Document:

<PAGE>

                                                                     EXHIBIT 4.1

                        -------------------------------

                          VASCULAR SCIENCES CORPORATION

                        -------------------------------

                              AMENDED AND RESTATED
                           INVESTORS' RIGHTS AGREEMENT

                                ----------------

                                  June 25, 2003

                                ----------------

<PAGE>

                          VASCULAR SCIENCES CORPORATION

                              AMENDED AND RESTATED
                           INVESTORS' RIGHTS AGREEMENT

      This Amended and Restated Investors' Rights Agreement (the "Agreement") is
made as of the 25TH day of June, 2003, by and among Vascular Sciences
Corporation, a Delaware corporation (the "Company"), the individuals and
entities listed on Schedule A attached hereto (each an "Investor," and
collectively, the "Investors"), and certain holders of the Company's Common
Stock listed on Schedule B attached hereto (the "Prior Holders"). This Agreement
shall become effective on the execution of that certain Secured Convertible Grid
Debenture Subscription Agreement dated as of June 25, 2003 (the "Debenture
Subscription Agreement"), by and among the Company, TLC Vision Corporation, a
New Brunswick corporation ("TLC") and Diamed Medizintechnik GMBH, a corporation
incorporated under the laws of Germany ("Diamed" and, together with TLC, the
"Debentureholders") and certain of the Prior Holders.

                                    RECITALS

      WHEREAS, concurrently herewith, the Company, the Debentureholders and
certain of the Prior Holders are entering into the Debenture Subscription
Agreement pursuant to which the Debentureholders will acquire secured
convertible grid debentures (the "Convertible Debentures") of the Company;

      WHEREAS, certain of the Investors hold shares of Series A Preferred Stock
(the "Series A Preferred Stock") of the Company and certain of the Investors
hold shares of Series B Preferred Stock (the "Series B Preferred Stock") of the
Company;

      WHEREAS, the Investors, the Prior Holders and the Company are parties to
an Investors' Rights Agreement dated as of July 25, 2002 ( the "Original
Investors' Rights Agreement") providing for certain registration rights, rights
of first refusal, board representation rights, rights to financial information
and certain other rights;

      WHEREAS, as a condition of entering into the Debenture Subscription
Agreement, the Debentureholders have requested that the Original Investors'
Rights Agreement be amended and restated on the terms set out herein to extend
certain rights and obligations to them in their capacities as Debentureholders
and Investors.

      NOW, THEREFORE, in consideration of the mutual promises and covenants and
agreements set forth herein, the Company and the Investors hereby agree as
follows:

                                    AGREEMENT

      1. Interpretation.

            1.1   Definitions.

            "ADDITIONAL SECURITIES" has the meaning attributed to it in Section
            4.1(c) or Section 4.2(c), as the case may be.

            "ADDITIONAL SUBSCRIBERS" has the meaning attributed to it in Section
            4.1(c) or Section 4.2(c), as the case may be.

<PAGE>

            "AGREEMENT" has the meaning attributed to it in the first paragraph
            of this amended and restated investors' rights agreement.

            "ASAHI NOTE" means the Secured Fixed Rate Note dated as of February
            28, 2001 by and between OccuLogix Corporation and Asahi Medical Co.,
            Ltd., as amended as of November 10, 2001 and November 30, 2002 and
            as assigned by OccuLogix Corporation to the Company;

            "BOARD DESIGNEE" has the meaning attributed to it in Section 6.3.

            "CHANGE OF CONTROL" means the occurrence of a transaction or a
            series of transactions as a result of which the Company becomes
            controlled by a Person or Persons other than the Debentureholders;
            for the purpose of the foregoing, the Company is controlled by a
            Person or Persons other than the Debentureholders if the
            Debentureholders, or either of them, no longer own Securities
            carrying more than 50% of the voting rights, on a fully-diluted
            basis, ordinarily exercisable at meetings of shareholders of the
            Company, such rights being sufficient to elect a majority of the
            directors of the Company.

            "CERTIFICATE OF INCORPORATION" means the amended and restated
            certificate of incorporation of the Company dated July 25, 2002 as
            may be further amended and restated from time to time.

            "COMPANY" has the meaning attributed to it in the first paragraph of
            this Agreement.

            "CONVERTIBLE DEBENTURES" has the meaning attributed to it in the
            recitals to this Agreement.

            "CONVERTIBLE SECURITIES" means securities convertible into,
            exchangeable for or otherwise carrying the right or obligation to
            acquire Common Stock, including the Convertible Debentures (and
            including the Share Purchase Option contained therein), the Series A
            Preferred Stock, the Series B Preferred Stock and any other rights,
            options or warrants to acquire Common Stock.

            "COMMON STOCK" means the Company's common stock as set forth in its
            Certificate of Incorporation and includes any shares of stock or
            securities into which Common Stock may be converted or changed or
            which result from a consolidation, subdivision, reclassification or
            redesignation of Common Stock.

            "DEBENTUREHOLDERS" has the meaning attributed to it in the first
            paragraph of this Agreement.

            "DEBENTURE REGISTRABLE SECURITIES" means (i) the Common Stock
            issuable or issued upon conversion of the Convertible Debentures and
            (ii) the Common Stock issuable or issued upon exercise of the Share
            Purchase Option, (iii) Common Stock issued as (or issuable upon the
            conversion or exercise of any warrant, right or other security which
            is issued as) a dividend or other distribution with respect

-2-
<PAGE>

            to, or in exchange for or in replacement of the shares referenced in
            (i) and (ii) above, excluding in all cases, however, any Debenture
            Registrable Securities sold or transferred by a Person in a
            transaction in which such Person's rights under Section 2 are not
            assigned or sold pursuant to Rule 144 promulgated under the
            Securities Act.

            "DEBENTURE REGISTRABLE SECURITIES THEN OUTSTANDING" means the sum of
            (i) the number of shares of Common Stock outstanding which are
            Debenture Registrable Securities and (ii) the number of shares of
            Common Stock which are issuable pursuant to then convertible or
            exercisable securities (including Convertible Debentures) and which
            are Debenture Registrable Securities.

            "DEBENTURE SUBSCRIPTION AGREEMENT" has the meaning attributed to it
            in the first paragraph of this Agreement.

            "DEMAND NOTICE" has the meaning attributed to it in Section
            2.1(a)(i).

            "DEMAND REQUEST" has the meaning attributed to it in Section 2.1(a).

            "DESIGNATOR" or "DESIGNATORS" has the meaning attributed to it in
            Section 6.3.

            "DIAMED" has the meaning attributed to it in the first paragraph of
            this Agreement.

            "DRAG-ALONG NOTICE" has the meaning attributed to it in Section
            4.5(a).

            "EXCHANGE ACT" has the meaning attributed to it in Section 2.8(a).

            "FIRST REFUSAL SHARES" has the meaning attributed to it in Section
            4.3(a).

            "FORM S-3" means such form under the Securities Act as is in effect
            on the date of this Agreement or any successor or similar
            registration form under the Securities Act subsequently adopted by
            the SEC which permits inclusion or incorporation of substantial
            information by reference to other documents filed by the Company
            with the SEC.

            "HOLDER" or "HOLDERS" means, for purposes of Section 2 and Section 3
            of this Agreement, any Investor owning of record Registrable
            Securities that have not been sold to the public or pursuant to Rule
            144 promulgated under the Securities Act or any assignee of record
            of such Registrable Securities to whom rights under Section 2 have
            been duly assigned in accordance with this Agreement; provided,
            however, that for purposes of this Agreement, a record holder of
            Series A Preferred Stock, Series B Preferred Stock or Convertible
            Debentures convertible into or exercisable for, as the case may be,
            such Registrable Securities shall be deemed to be the Holder of such
            Registrable Securities.

            "INITIAL ALLOTMENT" has the meaning attributed to it in Section
            4.1(a) or Section 4.2(a), as the case may be.

-3-
<PAGE>

            "INITIATING HOLDERS" has the meaning attributed to it in Section
            2.1(a).

            "INITIAL PUBLIC OFFERING" has the meaning attributed to it in
            Section 2.9.

            "INVESTOR" or "INVESTORS" has the meaning attributed to it in the
            first paragraph of this Agreement.

            "ISSUED SECURITIES" has the meaning attributed to it in Section
            4.2(a).

            "LISTED" means listed for trading on the NASDAQ National Market, the
            New York Stock Exchange or such other United States or Canadian
            stock exchange as is approved by the Board of Directors.

            "NET INCOME" has the meaning attributed to it in Section 6.4(b).

            "OFFERED SECURITIES" has the meaning attributed to it in Section
            4.1(a) or Section 4.2(a), as the case may be.

            "ORIGINAL INVESTORS' RIGHTS AGREEMENT" has the meaning attributed to
            it in the recitals to this Agreement.

            "PERSON" means any individual, corporation, partnership, limited
            liability company, limited liability partnership, firm, joint
            venture, association, joint-stock company, unincorporated
            organization, trust, trustee, executor, administrator or other legal
            personal representative, regulatory body or agency, government or
            governmental agency, authority or other entity howsoever designated
            or constituted.

            "PRIOR HOLDERS" has the meaning attributed to it in the first
            paragraph of this Agreement.

            "PROPORTIONATE INTEREST" of any Investor or Prior Holder means the
            percentage of the outstanding Common Stock then held by that
            Investor or Prior Holder, as the case may be, in relation to all
            Common Stock held by all Investors and Prior Holders, with all such
            holdings being calculated on a fully-diluted basis.

            "PROPOSED SELLER" has the meaning attributed to it in Section
            4.3(a).

            "PURCHASED SECURITIES" has the meaning attributed to it in Section
            5.1.

            "PURCHASE PRICE" has the meaning attributed to it in Section 5.3(a).

            "PURCHASER" has the meaning attributed to it in Section 5.1.

            "QUALIFIED IPO" means the first firmly committed underwritten public
            offering of the Company's Common Stock yielding net proceeds to the
            Company of at least $50,000,000, after deduction of underwriters
            commissions and expenses and a per share price of least $11.56594
            (as appropriately adjusted for stock splits, stock

-4-
<PAGE>

            dividends and recapitalizations and similar events) and provided
            that such shares of Common Stock are Listed.

            "REGISTER", "REGISTERED" and "REGISTRATION" refer to a registration
            effected by preparing and filing a registration statement or similar
            document in compliance with the Securities Act and the declaration
            or ordering of effectiveness of such registration statement or
            document.

            "REGISTRABLE SECURITIES" means the Series A Registrable Securities,
            the Series B Registrable Securities and the Debenture Registrable
            Securities.

            "REGISTRABLE SECURITIES THEN OUTSTANDING" shall mean the sum of (i)
            the number of Series A Registrable Securities then outstanding; (ii)
            the number of Series B Registrable Securities then outstanding; and
            (iii) the number of Debenture Registrable Securities then
            outstanding.

            "S-3 DEMAND REQUEST" has the meaning attributed to it in Section
            2.3(a).

            "SALE PRICE" has the meaning attributed to it in Section 4.3(a).

            "SEC" means the United States Securities and Exchange Commission.

            "SECURITIES" means Common Stock and Convertible Securities.

            "SECURITIES ACT" means the Securities Act of 1933, as amended.

            "SELLER" has the meaning attributed to it in Section 4.4.

            "SELLERS" has the meaning attributed to it in Section 4.5(a).

            "SELLER'S NOTICE" has the meaning attributed to it in Section
            4.3(a).

            "SERIES A PREFERRED STOCK" has the meaning attributed to it in the
            recitals to this Agreement.

            "SERIES A REGISTRABLE SECURITIES" means (i) the Common Stock
            issuable or issued upon conversion of the Series A Preferred Stock
            and (ii) any Common Stock issued as (or issuable upon the conversion
            or exercise of any warrant, right or other security which is issued
            as) a dividend or other distribution with respect to, or in exchange
            for or in replacement of the shares referenced in (i) above,
            excluding in all cases, however, any Series A Registrable Securities
            sold or transferred by a Person in a transaction in which such
            Person's rights under Section 2 are not assigned or sold pursuant to
            Rule 144 promulgated under the Securities Act.

            "SERIES A REGISTRABLE SECURITIES THEN OUTSTANDING" means the sum of
            (i) the number of shares of Common Stock outstanding which are
            Series A Registrable Securities and (ii) the number of shares of
            Common Stock which are issuable

-5-
<PAGE>

            pursuant to then convertible or exercisable securities (including
            Class A Preferred Stock) and which are Series A Registrable
            Securities.

            "SERIES B PREFERRED STOCK" has the meaning attributed to it in the
            recitals to this Agreement.

            "SERIES B PURCHASE AGREEMENT" means the Series B Preferred Stock
            Purchase Agreement dated as of July 25, 2002 by and among the
            Company, TLC and certain of the Prior Holders, as amended on June
            23, 2003, and as may be further amended and restated from time to
            time.

            "SERIES B REGISTRABLE SECURITIES" means (i) the Common Stock
            issuable or issued upon conversion of the Series B Preferred Stock
            and (ii) any Common Stock issued as (or issuable upon the conversion
            or exercise of any warrant, right or other security which is issued
            as) a dividend or other distribution with respect to, or in exchange
            for or in replacement of the shares referenced in (i) above,
            excluding in all cases, however, any Series B Registrable Securities
            sold or transferred by a Person in a transaction in which such
            Person's rights under Section 2 are not assigned or sold pursuant to
            Rule 144 promulgated under the Securities Act.

            "SERIES B REGISTRABLE SECURITIES THEN OUTSTANDING" means the sum of
            (i) the number of shares of Common Stock outstanding which are
            Series B Registrable Securities and (ii) the number of shares of
            Common Stock which are issuable pursuant to then convertible or
            exercisable securities (including Series B Preferred Stock) and
            which are Series B Registrable Securities.

            "SHARE PURCHASE OPTION" has the meaning attributed to it in the
            Convertible Debentures.

            "SPECIAL MEETING" has the meaning attributed to it in Section
            6.2(h).

            "SUBSCRIPTION NOTICE" has the meaning attributed to it in Section
            4.1(b).

            "SUBSCRIPTION OFFER" has the meaning attributed to it in Section
            4.1(a) or Section 4.2(a), as the case may be.

            "TAG-ALONG NOTICE" has the meaning attributed to it in Section 4.4.

            "TAG-ALONG SALE" has the meaning attributed to it in Section 4.4.

            "THIRD PARTY" has the meaning attributed to it in Section
            4.3(b)(ii).

            "THIRD PARTY PURCHASER" means, in relation to any Investor or Prior
            Holder, a person with whom such Investor or Prior Holder deals at
            arm's length.

            "TIME OF CLOSING" has the meaning attributed to it in Section 5.2.

-6-
<PAGE>

            "TLC" has the meaning attributed to it in the first paragraph of
            this Agreement.

            "UNSUBSCRIBED SECURITIES" has the meaning attributed to it in
            Section 4.1(c) or Section 4.2(c), as the case may be.

            "VENDOR" has the meaning attributed to it in Section 5.1.

            "VIOLATION" has the meaning attributed to it in Section 2.8(a).

            1.2 AMENDMENT AND RESTATEMENT OF PRIOR REGISTRATION AND
STOCKHOLDERS' RIGHTS. The Company and each undersigned Prior Holder and Investor
agrees and acknowledges that this Agreement hereby amends, restates, supercedes
and replaces any prior agreements, including, without limitation, the Original
Investors' Rights Agreement, between such Prior Holder or Investor, as the case
may be, and the Company (or any predecessor corporation of the Company) relating
to registration rights, rights of first refusal, board representation rights,
rights to financial information or any other rights described in this Agreement.

            1.3 CHANGE TO COMMON STOCK. The provisions of this Agreement
relating to Common Stock shall apply, mutatis mutandis, to any securities into
which such Common Stock may be converted, reclassified, redesignated,
subdivided, consolidated or otherwise changed from time to time and to any
securities of any successor or continuing corporation to the Company that may be
received in respect of any Common Stock on a reorganization, amalgamation,
consolidation or merger, statutory or otherwise.

            1.4 ADDITIONAL SECURITIES. Each party hereby agrees that all
Securities hereafter acquired by such party shall be subject in all respects to
the provisions of this Agreement.

            1.5 FULLY-DILUTED. For the purposes of this Agreement, wherever a
calculation is to be made on a "fully-diluted basis", the relevant calculation
shall be made on a pro forma basis after giving effect to or assuming the prior
conversion or exchange of, or the prior exercise of any right, option or
obligation to purchase or acquire any Common Stock attaching to, any Convertible
Securities, including, without limitation, the Share Purchase Option, then
outstanding by each holder of such Convertible Securities, regardless of whether
such conversion, exchange or exercise has in fact occurred.

            1.6 DEBENTUREHOLDERS DEEMED TO BE STOCKHOLDERS. Notwithstanding
anything to the contrary in the Company's constating documents or otherwise,
where the consent, approval or any process requiring a vote by the stockholders
of the Company is required, whether under this Agreement, at law or otherwise,
the Debentureholders shall be entitled to and shall vote on the basis that the
Debentureholders are holders of that number of shares of Common Stock to which
such Debentureholder would be entitled upon the full conversion and exercise of
its Convertible Debenture and Share Purchase Option, respectively. For greater
certainty, in addition to any other consent, approval or vote which may be
required by stockholders of the Company, the Company shall not take any action
with respect to any matter submitted for such consent, approval or vote, unless
the required threshold of consent, approval or vote is achieved taking into
account the Debentureholders' participation in such consent, approval or vote.

-7-
<PAGE>

      2. Registration Rights. The Company covenants and agrees as follows:

            2.1 Request for Registration.

                  (a) If the Company shall receive a written request (the
"Demand Request") from the Debentureholders (the "Initiating Holders") that the
Company file a registration statement under the Securities Act covering the
registration of Registrable Securities with an aggregate expected offering price
of at least $10,000,000, then the Company shall:

                        (i) within ten (10) calendar days of the receipt of the
Demand Request, give written notice of such request (the "Demand Notice") to all
Holders;

                        (ii) prepare and file as soon as practicable, and in any
event within forty-five (45) calendar days after the receipt of the Demand
Request, a registration statement under the Securities Act covering all
Registrable Securities which the Holders request to be registered (subject to
the limitations of subsection 2.1(b)) by written notice to the Company given
within twenty (20) calendar days after the giving of the Demand Notice; and

                        (iii) use its best efforts to cause the registration
statement to become effective as soon as practicable.

                  (b) If the Initiating Holders intend to distribute the
Registrable Securities covered by their request by means of an underwriting,
they shall so advise the Company as a part of their Demand Request and the
Company shall include such information in the Demand Notice. The underwriter
will be selected by the Company and shall be reasonably acceptable to the
Initiating Holders. In such event, the right of any Holder to include its
Registrable Securities in such registration shall be conditioned upon such
Holder's participation in such underwriting and the inclusion of such Holder's
Registrable Securities in the underwriting (unless otherwise mutually agreed by
the Initiating Holders and such Holder) to the extent provided herein. All
Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in subsection 2.4(f)) enter into an
underwriting agreement in customary form with the underwriter or underwriters
selected for such underwriting. Notwithstanding any other provision of this
Section 2.1, if the underwriter advises the Initiating Holders in writing that
marketing factors require a limitation of the number of shares to be
underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities which would otherwise be underwritten pursuant hereto,
and the number of shares of such Registrable Securities that may be included in
the underwriting shall be allocated in the following order:

                        (i) first, the Debenture Registrable Securities (pro
rata as between the Holders thereof based upon the number of Debenture
Registrable Securities owned by each such Holder, on a fully-diluted basis);

                        (ii) second, the Series B Registrable Shares (pro rata
as between the Holders thereof based upon the number of Series B Registrable
Shares owned by each such Holder, on a fully-diluted basis); and

-8-
<PAGE>

                        (iii) third, the Series A Registrable Shares (pro rata
as between the Holders thereof based upon the number of Series A Registrable
Shares owned by each such Holder, on a fully-diluted basis),

provided, however, that the number of shares of Registrable Securities to be
included in such underwriting shall not be reduced unless all other securities
are first entirely excluded from the underwriting.

                  (c) Notwithstanding the foregoing, if the Company shall
furnish to Holders requesting a registration statement pursuant to this Section
2.1 a certificate signed by the Chief Executive Officer of the Company stating
that, in the good faith judgment of the Board of Directors of the Company, it
would be seriously detrimental to the Company and its stockholders for such
registration statement to be filed and it is therefore essential to defer the
filing of such registration statement, the Company shall have the right to defer
taking action with respect to such filing for a period of not more than sixty
(60) calendar days after receipt of the Demand Request; provided, however, that
the Company may not utilize this right more than once in any 12-month period.

            2.2 Piggyback Registrations.

                  (a) The Company shall promptly notify all Holders of
Registrable Securities in writing at least thirty (30) calendar days prior to
filing any registration statement under the Securities Act for purposes of
effecting a public offering of securities of the Company (including, but not
limited to, registration statements relating to secondary offerings of
securities of the Company, but excluding registration statements on Forms S-4
and S-8 and any similar successor forms) and will afford each such Holder an
opportunity to include in such registration statement all or any part of the
Registrable Securities then held by such Holder. Each Holder desiring to include
in any such registration statement all or any part of the Registrable Securities
held by such Holder shall, within twenty (20) calendar days after receipt of the
above-described notice from the Company, so notify the Company in writing, and
in such notice shall inform the Company of the number of Registrable Securities
such Holder wishes to include in such registration statement. If a Holder
decides not to include all of its Registrable Securities in any registration
statement thereafter filed by the Company, such Holder shall nevertheless
continue to have the right to include any Registrable Securities in any
subsequent registration statement or registration statements as may be filed by
the Company with respect to offerings of its securities, all upon the terms and
conditions set forth herein.

                  (b) If a registration statement under which the Company gives
notice under this Section 2.2 is for an underwritten offering, then the Company
shall so advise the Holders of Registrable Securities. In such event, the right
of any such Holder's Registrable Securities to be included in a registration
pursuant to this Section 2.2 shall be conditioned upon such Holder's
participation in such underwriting and the inclusion of such Holder's
Registrable Securities in the underwriting to the extent provided herein. All
Holders proposing to distribute their Registrable Securities through such
underwriting shall enter into an underwriting agreement in customary form with
the managing underwriter or underwriter(s) selected for such underwriting.
Notwithstanding any other provision of this Agreement, if the managing
underwriter(s) determine(s) in good faith that marketing factors require a
limitation of the

-9-
<PAGE>

number of shares to be underwritten, then the managing underwriter(s) may
exclude shares (including Registrable Securities) from the registration and the
underwriting, and the number of shares that may be included in the registration
and the underwriting shall be allocated,

            (i)   first, to the Company,

            (ii)  second, to each of the Holders of Debenture Registrable
                  Securities requesting inclusion of their Debenture Registrable
                  Securities in such registration statement on a pro rata basis
                  based on the total number of Debenture Registrable Securities
                  then held by each such Holder on a fully-diluted basis,

            (iii) third, to each of the Holders of Series B Registrable
                  Securities requesting inclusion of their Series B Registrable
                  Securities in such registration statement on a pro rata basis
                  based on the total number of Series B Registrable Securities
                  then held by each such Holder on a fully-diluted basis,

            (iv)  fourth, to each of the Holders of Series A Registrable
                  Securities requesting inclusion of their Series A Registrable
                  Securities in such registration statement on a pro rata basis
                  based on the total number of Series A Registrable Securities
                  then held by each such Holder on a fully-diluted basis, and

            (v)   fifth, to any stockholder (other than a Holder) invoking
                  contractual rights to have their securities registered, if
                  any, on a pro rata basis,

but in no event shall the amount of securities of the selling Holders of
Convertible Debentures included in the offering be reduced below 30% of the
total amount of securities included in such offering, unless such offering is
the initial public offering of the Company's securities. If any Holder
disapproves of the terms of any such underwriting, such Holder may elect to
withdraw therefrom by written notice to the Company and the underwriter. Any
Registrable Securities excluded or withdrawn from such underwriting shall be
excluded and withdrawn from the registration and those Registrable Securities
will continue to be subject to the terms of this Agreement. For any Holder which
is a partnership or corporation, the partners, retired partners and shareholders
of such Holder, or the estates and family members of any such partners and
retired partners and any trusts for the benefit of any of the foregoing persons
shall be deemed to be a single "Holder," and any pro rata reduction with respect
to such "Holder" shall be based upon the aggregate amount of shares carrying
registration rights owned by all entities and individuals included in such
"Holder," as defined in this sentence.

            2.3 S-3 Registration.

                  (a) In case the Company shall receive, at any time and from
time to time after the Company is eligible to use Form S-3, from any Holder or
Holders a written request or requests (the "S-3 Demand Request") that the
Company effect a registration on Form S-3 and any related qualification or
compliance with respect to all or a part of the Registrable Securities owned by
such Holder or Holders, the Company shall:

-10-
<PAGE>

                        (i) promptly give written notice of the proposed
registration, and any related qualification or compliance, to all other Holders;
and

                        (ii) prepare and file as soon as practicable, and in any
event within thirty (30) calendar days after the receipt of the S-3 Demand
Request, a registration statement on Form S-3 and use its best efforts to, as
soon as practicable, effect such registration and all such qualifications and
compliances as may be so requested and as would permit or facilitate the sale
and distribution of all or such portion of such Holder's or Holders' Registrable
Securities as are specified in such request, together with all or such portion
of the Registrable Securities of any other Holder or Holders joining in such
request as are specified in a written request given within twenty (20) calendar
days after receipt of such written notice from the Company; provided, however,
that the Company shall not be obligated to effect any such registration,
qualification or compliance, pursuant to this Section 2.3: (i) if Form S-3 is
not available for such offering by the Holders; (ii) if the Holders, together
with the holders of any other securities of the Company entitled to inclusion
and electing to be included in such registration, propose to sell Registrable
Securities and such other securities (if any) at an aggregate price to the
public (net of any underwriters' discounts or commissions) of less than
$1,000,000; or (iii) if the Company shall furnish to the Holders a certificate
signed by the Chief Executive Officer of the Company stating that, in the good
faith judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its stockholders for such Form S-3 registration
to be effected at such time, in which event the Company shall have the right to
defer the filing of the Form S-3 registration statement for a period of not more
than sixty (60) calendar days after receipt of the request of the Holder or
Holders under this Section 2.3 (provided, however, that the Company shall not
utilize this right more than once in any 12-month period).

            2.4 OBLIGATIONS OF THE COMPANY. Whenever required to effect the
registration of any Registrable Securities under this Agreement, the Company
shall, as expeditiously as reasonably possible:

                  (a) prior to filing a registration statement with the SEC,
provide each selling Holder with a draft of the registration statement for its
review and comment;

                  (b) prepare and file with the SEC a registration statement
with respect to such Registrable Securities and use its best efforts to cause
such registration statement to become effective, and keep such registration
statement effective for up to one hundred eighty (180) calendar days; provided,
however, that such 180-day period shall be extended for a period of time equal
to the period the Holder refrains from selling any securities included in such
registration at the request of an underwriter of Common Stock (or other
securities of the Company);

                  (c) prepare and file with the SEC such amendments and
supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement;

                  (d) furnish to the Holders such number of copies of a
prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act,

-11-
<PAGE>

and such other documents as they may reasonably request in order to facilitate
the disposition of the Registrable Securities owned by them that are included in
such registration;

                  (e) use its best efforts to (i) register and qualify the
securities covered by such registration statement under such other securities or
"blue sky" laws of such jurisdictions as shall be reasonably requested by the
Holders, (ii) prepare and file in those jurisdictions such amendments (including
post-effective amendments) and supplements, and take such other actions, as may
be necessary to maintain such registration and qualification in effect at all
times for the period of distribution contemplated thereby and (iii) take such
further action as may be necessary or advisable to enable the disposition of the
Registrable Securities in such jurisdictions provided that the Company shall not
be required in connection therewith or as a condition thereto to qualify
generally to do business where it is not so qualified or to file a general
consent to service of process in any such states or jurisdictions;

                  (f) in the event of any underwritten public offering, enter
into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter(s) of such offering (it being
understood and agreed that, as a condition to the Company's obligations under
this clause (f), each Holder participating in such underwriting shall also enter
into and perform its obligations under such an agreement);

                  (g) immediately notify each Holder of Registrable Securities
covered by such registration statement at any time when a prospectus relating
thereto is required to be delivered under the Securities Act of the happening of
any event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material fact or
omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances
then existing and promptly file such amendments and supplements which may be
required on account of such event and use its best efforts to cause each such
amendment and supplement to become effective;

                  (h) immediately notify each seller of Registrable Securities
of the issuance by the SEC of any stop order suspending the effectiveness of the
registration statement or the initiation of any proceedings for that purpose and
make every reasonable effort to prevent the issuance of any stop order and, if
any stop order is issued, to obtain the lifting thereof at the earliest possible
time;

                  (i) furnish, at the request of any Holder requesting
registration of Registrable Securities, on the date that such Registrable
Securities are delivered to the underwriters for sale, if such securities are
being sold through underwriters, or, if such securities are not being sold
through underwriters, on the date that the registration statement with respect
to such securities becomes effective, (i) an opinion, dated as of such date, of
the counsel representing the Company for the purposes of such registration, in
form and substance as is customarily given to underwriters in an underwritten
public offering and reasonably satisfactory to a majority in interest, on a
fully-diluted basis, of the Holders requesting registration, addressed to the
underwriters, if any, and to the Holders requesting registration of Registrable
Securities and (ii) a "comfort" letter dated as of such date, from the
independent certified public accountants of the Company, in form and substance
as is customarily given by independent certified public accountants to
underwriters in an underwritten public offering and reasonably

-12-
<PAGE>

satisfactory to a majority in interest of the Holders, on a fully-diluted basis,
requesting registration, addressed to the underwriters, if any, and to the
Holders requesting registration of Registrable Securities;

                  (j) apply for listing and list the Registrable Securities
being registered on any national securities exchange on which a class of the
Company's equity securities is listed or, if the Company does not have a class
of equity securities listed on a national securities exchange, apply for
qualification and use its best efforts to qualify the Registrable Securities
being registered for inclusion on the automated quotation system of the National
Association of Securities Dealers, Inc.;

                  (k) make available for inspection by each seller of
Registrable Securities, any underwriter participating in any distribution
pursuant to such registration statement, and any attorney, accountant or other
agent retained by such seller or underwriter, all financial and other records,
pertinent corporate documents and properties of the Company, and cause the
Company's officers, directors and employees to supply all information reasonably
requested by any such seller, underwriter, attorney, accountant or agent in
connection with such registration statement;

                  (l) take all actions reasonably necessary to facilitate the
timely preparation and delivery of certificates (not bearing any legend
restricting the sale or transfer of such securities) representing the
Registrable Securities to be sold pursuant to the Registration Statement and to
enable such certificates to be in such denominations and registered in such
names as the Sellers or any underwriters may reasonably request; and

                  (m) take all other reasonable actions necessary to expedite
and facilitate the registration of the Registrable Securities pursuant to the
Registration Statement.

            2.5 EXPENSES. All expenses incurred in connection with
registrations, filings or qualifications pursuant to Sections 2.1, 2.2 and 2.3
(excluding underwriters' and brokers' discounts and commissions), including,
without limitation all registration, filing and qualification fees, printers'
and accounting fees, fees and disbursements of counsel for the Company and the
reasonable fees and disbursements of one (1) counsel for the selling Holder or
Holders shall be borne by the Company.

            2.6 FURNISH INFORMATION. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to Sections 2.1, 2.2 and
2.3 of this Agreement that the selling Holders shall furnish to the Company such
information regarding themselves, the Registrable Securities held by them and
the intended method of disposition of such securities as shall be required to
timely effect the registration of their Registrable Securities.

            2.7 DELAY OF REGISTRATION. No Holder shall have any right to obtain
or seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 2.

            2.8 INDEMNIFICATION. In the event any Registrable Securities are
included in a registration statement under Sections 2.1, 2.2 and 2.3 of this
Agreement:

                  (a) BY THE COMPANY. To the extent permitted by law, the
Company will indemnify and hold harmless each Holder, the partners, officers,
members, employees,

-13-
<PAGE>

agents and directors of each Holder, any underwriter (as defined in the
Securities Act) for such Holder and each Person, if any, who controls such
Holder or underwriter within the meaning of the Securities Act or the Securities
Exchange Act of 1934, as amended, (the "Exchange Act"), against any losses,
claims, damages, or liabilities (joint or several) to which they may become
subject under the Securities Act, the Exchange Act or other federal or state
law, insofar as such losses, claims, damages, or liabilities (or actions in
respect thereof) arise out of or are based upon any of the following statements,
omissions or violations (collectively a "Violation"):

                        (i) any untrue statement or alleged untrue statement of
a material fact contained in such registration statement, including any
preliminary prospectus or final prospectus contained therein or any amendments
or supplements thereto;

                        (ii) the omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements
therein not misleading; or

                        (iii) any violation or alleged violation by the Company
of the Securities Act, the Exchange Act, any federal or state securities law or
any rule or regulation promulgated under the Securities Act, the Exchange Act or
any federal or state securities law in connection with the offering covered by
such registration statement;

and the Company will reimburse each such Holder, partner, officer, member,
employee, agent or director, underwriter or controlling person for any legal or
other expenses reasonably incurred by them, as incurred, in connection with
investigating or defending any such loss, claim, damage, liability or action;
provided, however, that if the Company is found not to be liable for a Violation
and such Holder (or a partner, officer, member, employee, agent or director or
controlling person of such Holder) is found to be liable for such Violation,
such Holder shall pay the Company's legal or other expenses reasonably incurred
in defending any such loss, claim, damage, liability or action; provided further
that the indemnity agreement contained in this Section 2.8(a) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action
if such settlement is effected without the consent of the Company (which consent
shall not be unreasonably withheld), nor shall the Company be liable in any such
case for any such loss, claim, damage, liability or action to the extent that it
arises out of or is based upon a Violation which occurs in reliance upon and in
conformity with written information furnished expressly for use in connection
with such registration by such Holder, partner, officer, member, employee, agent
or director, underwriter or controlling person of such Holder.

                  (b) BY SELLING HOLDERS. To the extent permitted by law, each
selling Holder, severally and not jointly with any other Holder, will indemnify
and hold harmless the Company, each of its directors, each of its officers who
have signed the registration statement, each Person, if any, who controls the
Company within the meaning of the Securities Act, any underwriter and any other
Holder selling securities under such registration statement or any of such other
Holder's partners, directors or officers or any Person who controls such Holder
within the meaning of the Securities Act or the Exchange Act, against any
losses, claims, damages or liabilities (joint or several) to which the Company
or any such director, officer, controlling person, underwriter or other such
Holder, partner, officer, director, member, employee or agent or controlling
person of such other Holder may become subject under the Securities Act, the
Exchange Act or other federal or state law, insofar as such losses, claims,
damages or liabilities

-14-
<PAGE>

(or actions in respect thereto) arise out of or are based upon any Violation, in
each case to the extent (and only to the extent) that such Violation occurs in
reliance upon and in conformity with written information furnished by such
Holder expressly for use in connection with such registration; and each such
Holder will reimburse any legal or other expenses reasonably incurred by the
Company or any such partner, director, officer, member, employee, agent or
controlling person, underwriter or other Holder, partner, officer, director,
member, employee, agent or controlling person of such other Holder in connection
with investigating or defending any such loss, claim, damage, liability or
action; provided, however, that if the Holder is found not to be liable for a
Violation, the Company shall pay the Holder's legal or other expenses reasonably
incurred in defending any such loss, claim, damage, liability or action;
provided further that the indemnity agreement contained in this Section 2.8(b)
shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of the
Holder, (which consent shall not be unreasonably withheld), nor shall the
selling Holder be liable in any such case for any such loss, claim, damage,
liability or action to the extent that it arises out of or is based upon a
Violation which occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by
the Company, and provided further, that the total amounts payable in indemnity
by a Holder under this Section 2.8(b) in respect of any Violation shall not
exceed the net proceeds (after deduction of all underwriters' discounts and
commissions paid by such Holder in connection with the registration in question)
received by such Holder in the registered offering out of which such Violation
arises.

                  (c) NOTICE. Promptly after receipt by an indemnified party
under this Section 2.8 of notice of the commencement of any action (including
any governmental action), such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Section 2.8,
deliver to the indemnifying party a written notice of the commencement thereof
and the indemnifying party shall have the right to participate in, and, to the
extent the indemnifying party so desires, jointly with any other indemnifying
party similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party shall
have the right to retain its own counsel, with the fees and expenses to be paid
by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual
or potential conflict of interests between such indemnified party and any other
party represented by such counsel in such proceeding. The failure to deliver
written notice to the indemnifying party within a reasonable time of the
commencement of any such action, if prejudicial to its ability to defend such
action, shall relieve such indemnifying party of any liability to the
indemnified party under this Section 2.8, but the omission so to deliver written
notice to the indemnifying party will not relieve it of any liability that it
may have to any indemnified party otherwise than under this Section 2.8.

                  (d) CONTRIBUTION. In order to provide for just and equitable
contribution to joint liability under the Securities Act in any case in which
either (i) any Holder exercising rights under this Agreement, or any controlling
person of any such Holder, makes a claim for indemnification pursuant to this
Section 2.8 but it is judicially determined (by the entry of a final judgment or
decree by a court of competent jurisdiction and the expiration of time to appeal
or the denial of the last right of appeal) that such indemnification may not be
enforced in such case notwithstanding the fact that this Section 2.8 provides
for indemnification in such case,

-15-
<PAGE>

or (ii) contribution under the Securities Act may be required on the part of any
such selling Holder or any such controlling person in circumstances for which
indemnification is provided under this Section 2.8; then, and in each such case,
the Company and such Holder will contribute to the aggregate losses, claims,
damages or liabilities to which they may be subject (after contribution from
others) in such proportion so that such Holder is responsible for the portion
represented by the percentage that the public offering price of its Registrable
Securities offered by and sold under the registration statement bears to the
public offering price of all securities offered by and sold under such
registration statement, and the Company and other selling Holders are
responsible for the remaining portion; provided, however, that, in any such
case, (A) no such Holder will be required to contribute any amount in excess of
the public offering price of all such Registrable Securities offered and sold by
such Holder pursuant to such registration statement and (B) no Person or entity
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) will be entitled to contribution from any Person or entity
who was not guilty of such fraudulent misrepresentation.

                  (e) SURVIVAL. The obligations of the Company and Holders under
this Section 2.8 shall survive the completion of any offering of Registrable
Securities in a registration statement, and otherwise.

            2.9 "MARKET STAND-OFF" AGREEMENT. Each Holder hereby agrees that it
shall not, to the extent requested by the Company or an underwriter of
securities of the Company, offer, sell or otherwise transfer or dispose of or
engage in any other transaction regarding any Registrable Securities or other
shares of stock of the Company then owned by such Holder (other than to donees,
affiliates or partners of the Holder who agree to be similarly bound and except
for securities sold pursuant to such Registration Statement) for up to one
hundred eighty (180) calendar days following the effective date of the first
firmly underwritten public offering of Common Stock pursuant to a Registration
Statement filed with, and declared effective by, the SEC under the Securities
Act, on the terms and conditions approved by the Board of Directors (an "Initial
Public Offering"), and for up to ninety (90) calendar days following the
effective date in the case of subsequent public offerings; provided, however,
that the holders of more than 1% of the Company's capital stock, the Prior
Holders, and executive officers and directors of the Company then holding Common
Stock of the Company enter into similar agreements.

      In order to enforce the foregoing covenant, the Company shall have the
right to place restrictive legends on the certificates representing the shares
subject to this Section 2.9 and to impose stop transfer instructions with
respect to the Registrable Securities and such other shares of stock of each
Holder (and the shares or securities of every other Person subject to the
foregoing restriction) until the end of such period.

            2.10 RULE 144 REPORTING. With a view to making available the
benefits of certain rules and regulations of the SEC which may at any time
permit the sale of the Registrable Securities to the public without
registration, after such time as a public market exists for the Common Stock,
the Company agrees to:

                  (a) make and keep public information available, as those terms
are understood and defined in Rule 144 under the Securities Act, at all times
after the effective date that the Company becomes subject to the reporting
requirements of the Securities Act or the Exchange Act;

-16-
<PAGE>

                  (b) use its best efforts to file with the SEC in a timely
manner all reports and other documents required of the Company under the
Securities Act and the Exchange Act (at any time after it has become subject to
such reporting requirements); and

                  (c) furnish to any Holder forthwith upon request a written
statement by the Company as to its compliance with the reporting requirements of
Rule 144 (at any time after ninety (90) calendar days after the effective date
of the first registration statement filed by the Company for an offering of its
securities to the general public), and of the Securities Act and the Exchange
Act (at any time after it has become subject to such reporting requirements), a
copy of the most recent annual or quarterly report of the Company and such other
reports, documents of the Company or other information in the possession of or
reasonably obtainable by the Company as a Holder may reasonably request in
availing itself of any rule or regulation of the SEC allowing a Holder to sell
any such securities without registration.

            2.11 TERMINATION OF THE COMPANY'S OBLIGATIONS. The Company shall
have no obligations pursuant to Section 2 with respect to: (i) any request or
requests for registration made by any Holder on a date more than five (5) years
after the closing date of the Company's Initial Public Offering, or (ii) any
Registrable Securities proposed to be sold by a Holder in a registration
pursuant to Section 2 if in the opinion of counsel to the Company, all such
Registrable Securities proposed to be sold by a Holder may be sold in a ninety
(90) day period without registration under the Securities Act pursuant to Rule
144 under the Securities Act. Notwithstanding the foregoing, in no event shall a
Holder's registration rights terminate prior to the end of the end of the lock
up period provided for in Section 2.9.

            2.12 LIMITATIONS ON SUBSEQUENT REGISTRATION RIGHTS. From and after
the date of this Agreement, the Company shall not, without the prior written
consent of the Debentureholders, enter into any agreement with any holder or
prospective holder of any securities of the Company that provides such holder or
prospective holder with registration rights superior or equal to the
registration rights provided to the Investors pursuant to this Section 2.

      3. Assignment, Amendment and Restriction on Transfer.

            3.1 ASSIGNMENT. Notwithstanding anything herein to the contrary, the
registration rights of a Holder under Section 2, the pre-emptive rights, right
of first refusal, tag-along rights and drag along rights under Section 4 and the
information rights under Section 6 may be assigned only to (i) a party who
acquires at least three hundred thousand (300,000) shares of Registrable
Securities, on a fully-diluted basis, or (ii)(A) a shareholder, partner, member,
affiliate or beneficiary of such Holder; (B) a spouse, child, parent or
beneficiary of the estate of such Holder or (C) a trust for the benefit of the
persons set forth in (A) or (B); provided, however, that no party may be
assigned any of the foregoing rights unless the Company is given written notice
by the assigning party within five (5) calendar days after such assignment
stating the name, address and tax identification number, if any, of the assignee
and identifying the securities of the Company as to which the rights in question
are being assigned; and provided further that any such assignee (i) shall
receive such assigned rights subject to all the terms and conditions of this
Agreement, including without limitation the provisions of this Section 3, and
(ii) is not a competitor of the Company as determined in good faith by the
Company's Board of Directors.

            3.2 AMENDMENT OF REGISTRATION RIGHTS. Any provision of this
Agreement may be amended and the observance thereof may be waived (either
generally or in a particular

-17-
<PAGE>

instance and either retroactively or prospectively), only with the written
consent of: (i) the Company, (ii) the Debentureholders, (iii) the Holders
(and/or any of their permitted successors or assigns) of at least two-thirds of
Series B Registrable Securities then outstanding, and (iv) the Holders (and/or
any of their permitted successors or assigns) of at least a majority of the
Series A Registrable Securities then outstanding. Any amendment or waiver
effected in accordance with this Section 3.2 shall be binding upon each Investor
and each permitted successor or assignee of such Investor or Holder and the
Company; provided, however, that no waiver which adversely affects the rights of
any Investor or Holder disproportionately relative to the other Investors or
Holders shall be effective against such party unless such party has given its
consent to such waiver.

            3.3 GENERAL RESTRICTION ON TRANSFER. Except as otherwise permitted
in Section 4.8 of the Series B Purchase Agreement, Section 4.8 of the Debenture
Subscription Agreement and Section 4.3 of this Agreement, no securities of the
Company or any beneficial interest therein shall be sold, transferred, assigned,
mortgaged, pledged, charged, hypothecated or otherwise encumbered or disposed of
by any Investor or Prior Holder whether by operation of law or otherwise, except
with the prior written approval of the Board of Directors, or as expressly
required or permitted pursuant to the provisions of this Agreement, and any
action in contravention of this Section 3.3 shall be void.

      4.    Pre-emptive Rights; Right to Maintain Proportionate Holding; Right
            of First Refusal.

            4.1 Pre-Emptive Rights.

                  (a) Except as otherwise provided in Section 4.1(f), if the
Company proposes to issue any Securities (the "Offered Securities"), the Company
shall first offer (the "Subscription Offer") the Offered Securities for
subscription and purchase by the Investors and the Prior Holders, in each case
as nearly as may be offered (disregarding fractional interests) on a pro rata
basis in proportion to their respective Proportionate Interests at that date (in
this Section 4.1, the "Initial Allotment"), at such price as the Board of
Directors of the Company may determine.

                  (b) The Subscription Offer shall be made in writing by the
Company to each Investor and Prior Holder and shall (i) specify the price at
which the Offered Securities are offered, the amount of Offered Securities which
represents such Investor's or Prior Holders' Initial Allotment and the date on
which the purchase of the Offered Securities by the Investors and the Prior
Holders is to be completed, (ii) contain a summary of the principal attributes
of the Offered Securities (if other than Common Stock), (iii) state that any
Investor or Prior Holder who wishes to subscribe for Offered Securities must
give written notice (a "Subscription Notice") to that effect to the Company
within 20 calendar days after the date of the Subscription Offer, (iv) state
that any Investor or Prior Holder who wishes to subscribe for an amount of
Offered Securities different than its Initial Allotment must specify, in its
Subscription Notice, the amount of Offered Securities that it wishes to purchase
and (v) state that, unless the Investors and Prior Holders subscribe for all the
Offered Securities, the Company may elect not to sell any Offered Securities
under the Subscription Offer.

                  (c) If any Investors or Prior Holders do not subscribe in the
manner provided above for all of their Initial Allotments, the unsubscribed
Offered Securities (in this

-18-
<PAGE>

Section 4.1, the "Unsubscribed Securities") shall be applied to satisfy the
subscriptions of Investors or Prior Holders (in this Section 4.1, "Additional
Subscribers") for Offered Securities in excess of their Initial Allotments (in
this Section 4.1, "Additional Securities"). If the amount of Unsubscribed
Securities is less than the amount of Additional Securities subscribed for by
the Additional Subscribers, the Unsubscribed Securities shall be allocated among
the Additional Subscribers as nearly as may be (disregarding fractional
interests) on a pro rata basis based on the proportion that the number of shares
of Common Stock held by each Additional Subscriber at the date of the
Subscription Offer bears to the total number of shares of Common Stock held by
all Additional Subscribers at that date, with all such holdings being calculated
on a fully-diluted basis; provided, however, that the amount of Unsubscribed
Securities allocated to any Additional Subscriber shall not exceed the amount of
Additional Securities subscribed for by such Additional Subscriber as specified
in its Subscription Notice.

                  (d) If Offered Securities are subscribed for by the Investors
or Prior Holders in accordance with this Section 4.1, each Investor and Prior
Holder shall purchase the amount of Offered Securities subscribed for by and
allocated to it and the Company shall issue and sell such Offered Securities to
such Investor or Prior Holder on the closing date specified in the Subscription
Offer and otherwise on the terms specified in the Subscription Offer.

                  (e) If less than all the Offered Securities are subscribed for
by the Investors and Prior Holders in accordance with this Section 4.1, unless
the Company determines not to proceed with the issuance and sale of the Offered
Securities, the Company shall complete the issuance and sale of the Offered
Securities subscribed for by the Investors and Prior Holders as contemplated by
Section 4.1(d) and may offer and sell the unsubscribed portion of the Offered
Securities to such persons as the Board of Directors of the Company may
determine provided that (A) any such sale is completed within 90 days after the
expiry of the period of 20 calendar days for the giving of Subscription Notices,
(B) the price at which any Offered Securities are sold is not less than the
subscription price offered to the Investors and (C) each purchaser becomes a
party to this Agreement. After the expiry of such 90-day period, the foregoing
provisions of this Section 4.1 shall again apply to any proposed issuance of
Securities by the Company.

                  (f) The pre-emptive rights in this Section 4.1 shall not be
applicable to (i) the issuance or sale of shares of Common Stock (or options
therefor) to employees, directors and consultants for the primary purpose of
soliciting or retaining their services, pursuant to plans or agreements approved
by a majority of the Board of Directors of the Company, (ii) the issuance of
securities upon the conversion of shares of the Company's preferred stock,
conversion of the Convertible Debentures or exercise of the Share Purchase
Option, (iii) the issuance of securities to persons or entities with which the
Company has business relationships in connection with bona fide arm's length
equipment leasing arrangements, bank or institutional loans or other bona fide
arm's length transactions wherein the principal purpose of the issuance of such
securities is for non-equity financing purposes, so long as all such
arrangements and transactions are approved by a majority of the Board of
Directors of the Company (including at least one (1) Debentureholder nominee),
(iv) the issuance of securities pursuant to currently outstanding (as of the
date of this Agreement) options, warrants or notices to acquire securities of
the Company, (v) the issuance of securities in connection with a bona fide arm's
length business acquisition of or by the Company, whether by merger,
consolidation, sale of assets, sale or

-19-
<PAGE>

exchange of stock or otherwise, as approved by a majority of the Board of
Directors of the Company (including at least one (1) Debentureholder nominee),
or (vi) the issuance of securities pursuant to a Qualified IPO.

                  (g) The covenants set forth in this Section 4.1 shall
terminate and be of no further force and effect after the closing of the
Qualified IPO.

            4.2 Right to Maintain Proportionate Holding.

                  (a) In addition to any rights an Investor or Prior Holder may
have pursuant to Section 4.1, if the Company issues any Securities (the "Issued
Securities"), the Company shall offer (in this Section 4.2, the "Subscription
Offer") each Investor and Prior Holder the right to subscribe, at a price per
Security equal to the price received by the Company per Issued Security, for
such number (in this Section 4.2, the "Initial Allotment") of Securities (in
this Section 4.2, the "Offered Securities") of the same type and class as the
Issued Securities as is necessary to ensure that such Investor's or Prior
Holder's percentage ownership of the outstanding Common Stock, on a
fully-diluted basis after giving effect to the issuance of the Issued Securities
and any additional securities subscribed for pursuant to this Section 4.2, is
equal to such Investor's or Prior Holder's percentage ownership of the
outstanding Common Stock, on a fully-diluted basis, immediately prior to the
issuance of the Issued Securities.

                  (b) The Subscription Offer shall be made in writing by the
Company to each Investor and Prior Holder and shall (i) specify the price at
which the Offered Securities are offered, the amount of Offered Securities which
represents such Investor's or Prior Holders' Initial Allotment and the date on
which the purchase of the Offered Securities by the Investors and the Prior
Holders is to be completed, (ii) contain a summary of the principal attributes
of the Offered Securities (if other than Common Stock), (iii) state that any
Investor or Prior Holder who wishes to subscribe for Offered Securities must
give a Subscription Notice to that effect to the Company within 20 calendar days
after the date of the Subscription Offer and (iv) state that any Investor or
Prior Holder who wishes to subscribe for an amount of Offered Securities
different than its Initial Allotment must specify, in its Subscription Notice,
the amount of Offered Securities that it wishes to purchase.

                  (c) If any Investors or Prior Holders do not subscribe in the
manner provided above for all of their Initial Allotments, the unsubscribed
Offered Securities (in this Section 4.2, the "Unsubscribed Securities") shall be
applied to satisfy the subscriptions of Investors or Prior Holders (in this
Section 4.2 "Additional Subscribers") for Offered Securities in excess of their
Initial Allotments (in this Section 4.2, "Additional Securities"). If the amount
of Unsubscribed Securities is less than the amount of Additional Securities
subscribed for by the Additional Subscribers, the Unsubscribed Securities shall
be allocated among the Additional Subscribers as nearly as may be (disregarding
fractional interests) on a pro rata basis based on the proportion that the
number of shares of Common Stock held by each Additional Subscriber at the date
of the Subscription Offer bears to the total number of shares of Common Stock
held by all Additional Subscribers at that date, with all such holdings being
calculated on a fully-diluted basis; provided, however, that the amount of
Unsubscribed Securities allocated to any Additional Subscriber shall not exceed
the amount of Additional Securities subscribed for by such Additional Subscriber
as specified in its Subscription Notice.

-20-
<PAGE>

                  (d) If Offered Securities are subscribed for by the Investors
or Prior Holders in accordance with this Section 4.2, each Investor and Prior
Holder shall purchase the amount of Offered Securities subscribed for by and
allocated to it and the Company shall issue and sell such Offered Securities to
such Investor or Prior Holder on the closing date specified in the Subscription
Offer and otherwise on the terms specified in the Subscription Offer.

                  (e) The rights in this Section 4.2 shall not be applicable to
(i) the issuance or sale of shares of Common Stock (or options therefor) to
employees, directors and consultants for the primary purpose of soliciting or
retaining their services, pursuant to plans or agreements approved by a majority
of the Board of Directors of the Company, (ii) the issuance of securities upon
the conversion of shares of the Company's preferred stock, conversion of the
Convertible Debentures or exercise of the Share Purchase Option, (iii) the
issuance of securities to persons or entities with which the Company has
business relationships in connection with bona fide arm's length equipment
leasing arrangements, bank or institutional loans or other bona fide arm's
length transactions wherein the principal purpose of the issuance of such
securities is for non-equity financing purposes, so long as all such
arrangements and transactions are approved by a majority of the Board of
Directors of the Company (including at least one (1) Debentureholder nominee),
(iv) the issuance of securities pursuant to currently outstanding (as of the
date of this Agreement) options, warrants or notices to acquire securities of
the Company, (v) the issuance of securities in connection with a bona fide arm's
length business acquisition of or by the Company, whether by merger,
consolidation, sale of assets, sale or exchange of stock or otherwise, as
approved by a majority of the Board of Directors of the Company (including at
least one (1) Debentureholder nominee), or (vi) the issuance of securities
pursuant to a Qualified IPO. For greater certainty, the rights in this Section
4.2 shall be applicable to any issuance of Securities relating to the Asahi
Note.

                  (f) The covenants set forth in this Section 4.2 shall
terminate and be of no further force and effect after the closing of the
Qualified IPO.

            4.3 Right of First Refusal of Sales by Investors.

                  (a) If an Investor (the "Proposed Seller") intends to sell any
of such Investor's Series B Preferred Stock or Series B Registrable Securities
(other than the sale or transfer of such securities as otherwise permitted in
Section 4.8 of the Series B Purchase Agreement), the Proposed Seller shall give
written notice (the "Seller's Notice") to the Company stating that the Proposed
Seller intends to make such a sale or transfer, specifying the number of shares
of Series B Preferred Stock or Series B Registrable Securities (the "First
Refusal Shares"), and specifying the per share purchase price (payable in cash)
which the Proposed Seller is willing to accept for the First Refusal Shares (the
"Sale Price").

                  (b) Upon receipt of the Seller's Notice, the Company shall
have the irrevocable and exclusive right, exercisable by notice given to the
Proposed Seller within twenty (20) calendar days of its receipt of the Seller's
Notice:

                        (i) to agree that it will purchase all the First Refusal
Shares at the Sale Price and on the terms of payment set out in the Seller's
Notice; or

-21-
<PAGE>

                        (ii) to agree that the Proposed Seller may sell all the
First Refusal Shares held by it to a Person acting bona fide and at arm's length
with the Proposed Seller (a "Third Party") on terms and conditions no more
favorable to the Third Party than those contained in the Seller's Notice,
provided that, prior to completion of such sale, such Third Party become subject
to all of the obligations of the Proposed Seller under this Agreement and agree
to be bound by all of the provisions hereof in which case such Third Party shall
become entitled to exercise all the rights of the Proposed Seller under this
Agreement.

      If no notice is given by the Company under Section 4.3(b)(i), the Company
shall be deemed to have given the notice referred to in Section 4.3(b)(ii).

                  (c) If the Company gives the notice referred to in Section
4.3(b)(i), the purchase and sale of the First Refusal Shares shall be completed
on the 5th business day after the Company has agreed that it will purchase all
the First Refusal Shares held by the Proposed Seller.

                  If (i) the Company agrees that the Proposed Seller may sell
the First Refusal Shares held by it to a Third Party, or (ii) the Company does
not purchase all the First Refusal Shares in accordance with Section 4.3(c),
then, for a period of ninety (90) business days from the date of the Seller's
Notice, the Proposed Seller shall be entitled to sell the First Refusal Shares
held by it to a Third Party. Any transfer of the First Refusal Shares by the
Proposed Seller after the end of such ninety (90) business day period or any
change in the terms of the sale as set forth in the Seller's Notice which is
more favorable to such Third Party shall require a new notice of intent to
transfer to be delivered to the Company and shall give rise anew to the rights
provided in the preceding paragraphs.

                  (d) The covenants set forth in this Section 4.3 shall
terminate and be of no further force and effect after the closing of the
Qualified IPO.

            4.4 TAG-ALONG RIGHTS. If an Investor or Prior Holder (the "Seller")
proposes to sell, whether in a single transaction or a series of transactions,
(a "Tag-Along Sale") Securities to a Third Party Purchaser(s) (subject to prior
satisfaction of Section 4.3, if applicable) and the sale of such Securities
constitutes a Change of Control and no Drag-Along Notice is given to the other
Investors and Prior Holders pursuant to Section 4.5 in respect of such proposed
sale, each other Investor and Prior Holder shall have the right, exercisable by
giving written notice (the "Tag-Along Notice") to the Seller within 10 days
after the expiry of the 20 calendar day period referred to in Section 4.3, to
sell to the Third Party Purchaser up to that number of Securities which equals
(disregarding fractions) the total number of Securities which the Third Party
Purchaser is prepared to purchase as specified in its Third Party Offer
multiplied by a fraction, the numerator of which is the number of shares of
Common Stock owned by such Investor or Prior Holder and the denominator of which
is the total number of shares of Common Stock owned by the Seller and all other
Investors and Prior Holders giving a Tag-Along Notice to the Seller pursuant to
this Section 4.4, each calculated on a fully-diluted basis. Each such other
Investor or Prior Holder that elects to participate in the Tag-Along Sale shall
sell the Securities indicated in its Tag-Along Notice for the same consideration
per Security and otherwise on the same terms and conditions, mutatis mutandis,
as those specified in the Third Party Offer. The number of Securities to be sold
by the Seller to the Third Party Purchaser shall be equal to the difference
between the number of Securities that the other Investors and Prior Holders are

-22-
<PAGE>

entitled to sell to the Third Party Purchaser pursuant to this Section 4.4 and
the total number of Securities which the Third Party Purchaser is prepared to
purchase as specified in its Third Party Offer. The Seller shall not be
responsible for any failure by the Third Party Purchaser to complete the
Tag-Along Sale but shall not sell any Securities to the Third Party Purchaser
unless the Securities to be sold by those other Investors and Prior Holders (if
any) that elect to participate in the Tag-Along Sale are purchased by the Third
Party Purchaser at the same time in accordance with the provisions of this
Section 4.4. Unless the Board of Directors of the Company otherwise determines,
the sale of any Securities pursuant to this Section 4.4 shall be conditional on
any Third Party Purchaser becoming a party to this Agreement.

            4.5 Drag-Along Rights.

                  (a) If any of the Investors or Prior Holders (in this Section
4.5, the "Sellers") propose to sell all (but not less than all) of their
Securities to a Third Party Purchaser as permitted under Section 4.3 and such
Securities represent at least 66-2/3% of the outstanding Common Stock,
calculated on a fully-diluted basis, the Sellers may, by giving written notice
(a "Drag-Along Notice") to the other Investors and Prior Holders, require each
of the other Investors and Prior Holders to sell all (but not less than all) of
their Securities to the Third Party Purchaser for the same consideration per
Security and otherwise on the same terms and conditions, mutatis mutandis, as
those specified in the Third Party Offer;

                  (b) The Sellers shall not be responsible for any failure by
the Third Party Purchaser to complete the transactions contemplated by its Third
Party Offer but shall not sell any Securities to the Third Party Purchaser
unless the Securities to be sold by the other Investors and Prior Holders are
purchased by the Third Party Purchaser at the same time in accordance with the
provisions of this Section 4.

      5.    Closing Arrangements.

            5.1 DEFINITIONS. In this Section 5, the term "Purchased Securities"
means any Securities of the Company to be purchased from any Investor or Prior
Holder by any other party (including the Company) pursuant to this Agreement,
and the terms "Vendor" and "Purchaser" mean, respectively, the vendor and the
purchaser of Purchased Securities.

            5.2 PLACE AND TIME OF CLOSING. Unless otherwise provided in this
Agreement, the closing of the purchase and sale of the Purchased Shares shall
occur at the registered office of the Company at 1:00 p.m. (New York time) on
the tenth Business Day after the day on which the Vendor and the Purchaser first
became obliged to carry out such transaction or at such other place and time as
the Vendor and the Purchaser may mutually determine, the actual time of closing
on the closing date being hereinafter referred to as the "Time of Closing".

            5.3 CLOSING DELIVERIES. At the Time of Closing, subject to the other
provisions of this Agreement:

                  (a) the Purchaser shall pay the purchase price for the
Purchased Securities (the "Purchase Price") as determined in accordance with the
relevant provisions of this Agreement by bank draft or certified cheque; and

                  (b) the Vendor shall deliver to the Purchaser:

                        (i) a receipt for payment of the Purchase Price;

-23-
<PAGE>

                        (ii) the certificates or instruments representing the
Purchased Securities, duly endorsed for transfer; and

                        (iii) a warranty from the Vendor, in form satisfactory
to the Purchaser, acting reasonably, that the Vendor is the registered and
beneficial owner of the Purchased Securities, free and clear of any lien,
charge, pledge, security interest, adverse claim or other encumbrance.

            5.4 TENDER PROCESS. If the Vendor is not present at the Time of
Closing or is present but fails for any reason to deliver to the Purchaser any
document referred to in Section 5.3, the Purchaser may deposit the Purchase
Price into a special account at any branch of the Company's bank in the joint
names of the Vendor and the Purchaser. Forthwith after the making of such
deposit, the Purchaser shall give the Vendor written notice thereof, which
notice shall specify the date of deposit, the name and address of the bank at
which the deposit was made and the account number. Such deposit shall constitute
valid payment and satisfaction of the Purchase Price even though the Vendor may
have encumbered or disposed of any of the Purchased Securities and even though
the certificates or instruments representing the Purchased Securities may have
been delivered to any pledgee, transferee or other person. Upon presentation by
the Vendor to the Purchaser of the documents referred to in Section 5.3, the
Vendor shall be entitled to be paid the monies so deposited, without interest.
All interest in respect of any such bank account shall belong to the Purchaser.

            5.5 TRANSFER OF TITLE. If, pursuant to Section 5.4, the Purchase
Price is deposited with the Company's bank in the joint names of the Vendor and
the Purchaser, from and after the date of such deposit, and even though the
certificates or instruments representing the Purchased Securities may not have
been delivered to the Purchaser, the purchase and sale of the Purchased
Securities shall be deemed to have been completed and all right, title, benefit
and interest, both at law and in equity, in and to the Purchased Securities
shall be conclusively deemed to have been transferred and assigned to and become
vested in the Purchaser and all right, title, benefit and interest, legal or
equitable, therein or thereto of the Vendor, or of any pledgee, transferee or
other person claiming through the Vendor, shall cease.

            5.6 Payment in Satisfaction of Indebtedness.

                  (a) Without in any way limiting the restriction in Section
3.3, where the Vendor is unable to deliver the certificates or instruments
representing the Purchased Securities because any Purchased Securities have been
pledged as security for any indebtedness of the Vendor, the Purchaser may,
instead of depositing the Purchase Price into a special bank account as provided
in Section 5.4, pay all or a portion of the Purchase Price to discharge the
indebtedness secured thereby and to obtain a release of the relevant security
interest. Any such payment by the Purchaser shall constitute a complete
discharge of the Purchaser's obligation to pay to the Vendor a corresponding
amount of the Purchase Price.

                  (b) If the Purchaser pays only part of the Purchase Price to a
secured party pursuant to Section 5.6(a), the Purchaser may deposit an amount
equal to the balance of the Purchase Price into a special bank account in
accordance with the provisions of Section 5.4 and the provisions of Section 5.5
shall apply, mutatis mutandis, to the portion of the Purchase Price so
deposited.

-24-
<PAGE>

                  (c) If, following any payment by the Purchaser to a secured
party pursuant to Section 5.6(a), the balance, if any, of the Purchase Price is
either paid to the Vendor or deposited in a special bank account as provided in
Section 5.4, from and after the date of the last to occur of such payment and
such deposit, and even though the certificates or instruments representing the
Purchased Securities may not have been delivered to the Purchaser, the purchase
and sale of the Purchased Securities shall be deemed to have been completed and
all right, title, benefit and interest, both at law and in equity, in and to the
Purchased Securities shall be conclusively deemed to have been transferred and
assigned to and become vested in the Purchaser and all right, title, benefit and
interest, legal or equitable, therein or thereto of the Vendor, or of any
pledgee, transferee or other person claiming through the Vendor, shall cease.

                  (d) If the Vendor is indebted to the Company at the Time of
Closing, the Vendor hereby irrevocably directs the Purchaser to pay all or the
relevant portion of the Purchase Price to the Company to discharge such
indebtedness. Any such payment to the Company by the Purchaser shall constitute
a complete discharge of the Purchaser's obligation to pay to the Vendor all or
the relevant portion, as the case may be, of the Purchase Price.

            5.7 POWER OF ATTORNEY. The Vendor hereby irrevocably makes,
constitutes and appoints the Company or any officer of the Company as the
Vendor's true and lawful attorney with power to, in the name and on behalf of
the Vendor, execute and deliver all such assignments, transfers, instruments and
other documents as may be necessary effectively to transfer and assign the
Purchased Securities, or any part thereof, to the Purchaser on the books of the
Company. The appointment of the Company as the Vendor's attorney, and each and
every one of its rights and powers, being coupled with an interest, is
irrevocable.

      6.    Information, Board Rights and Business and Finance of the Company.

            6.1 Financial Statements and Reports.

                  (a) The Company will maintain true books and records of
account in which full and correct entries will be made of all its business
transactions pursuant to a system of accounting established and administered in
accordance with generally accepted accounting principles consistently applied,
and will set aside on its books all such proper accruals and reserves as shall
be required under generally accepted accounting principles consistently applied.

                  (b) The Company shall deliver to the Debentureholders and each
Investor that continues to hold not less than three hundred thousand (300,000)
shares of Registrable Securities, on a fully-diluted basis:

                        (i) As soon as practicable after the end of each fiscal
year of the Company, and in any event within ninety (90) calendar days
thereafter an audited consolidated balance sheet of the Company and its
subsidiaries, if any, at the end of such fiscal year and audited consolidated
statements of income, stockholders' equity and cash flows for such fiscal year,
which year-end financial reports shall be in reasonable detail prepared in
accordance with generally accepted accounting principles setting forth in each
case in comparative form the figures for the previous year and such financial
statements shall be accompanied by a report and opinion thereon by independent
chartered accountants of national standing selected by the Company's Board of
Directors (including at least one (1) Debentureholder nominee);

-25-
<PAGE>

                        (ii) As soon as practicable after the end of each month,
and in any event within thirty (30) calendar days after the end of each month
and as soon as practicable after the end of each fiscal quarter of the Company,
and in any event within forty-five (45) calendar days thereafter, an unaudited
consolidated balance sheet of the Company and its subsidiaries, as at the end of
such period, and a consolidated statement of income, stockholders' equity and
cash flows for such period and for the current fiscal year to date, each
certified by the Company's Chief Financial Officer, and all such statements
shall be in reasonable detail and prepared in accordance with generally accepted
accounting principles, except that they may not contain full footnote
disclosures and may be subject to normal year-end adjustments for recurring
accruals;

                        (iii) Prior to thirty (30) calendar days before the end
of each fiscal year, an operating budget for the next fiscal year; and

                        (iv) Any other business or financial information
regarding the Company that is reasonably requested by a Debentureholder.

                  (c) Each Investor agrees that any information obtained by the
Investor pursuant to this Section 6.1 which is reasonably perceived to be
proprietary to the Company or otherwise confidential will not, unless such
Investor shall otherwise be required by a court, governmental agency, any law or
the rules of any national securities exchange or association, be disclosed
without the prior written consent of the Company (so long as such information is
not in the public domain), provided that the Debentureholders may disclose such
proprietary or confidential information to their directors, officers, employees
and agents on a need to know basis, including for purposes of evaluating their
investment in the Company.

                  (d) For so long as an Investor is eligible to receive reports
under this Section 6.1, such Investor, or any authorized representative thereof,
shall have the right to visit and inspect the Company's properties, to examine
its books of account and records and to discuss its business and finances with
officers of the Company, all at such reasonable times and as often as may be
reasonably requested; provided, however, that each Investor agrees to use, and
to use its reasonable efforts to ensure that its authorized representatives use,
the same degree of care as such Investor uses to protect its own confidential
information and to keep confidential any information furnished to it which the
Company reasonably considers as confidential or proprietary and which has been
identified by the Company to the Investor as such (so long as such information
is not in the public domain), provided that the Debentureholders may disclose
such proprietary or confidential information to their directors, officers,
employees and agents on a need to know basis, solely for the purpose of
evaluating and monitoring their investment in the Company. Each Investor shall
pay any expenses incurred by it in connection with its discussions of the
affairs, finances and accounts of the Company.

                  (e) The covenants set forth in this Section 6.1 shall
terminate and be of no further force and effect after the closing of the
Qualified IPO.

-26-
<PAGE>

            6.2 Board of Directors and Voting Agreement.

                  (a) The Investors and Prior Holders covenant and agree to at
all times vote or cause to be voted all shares of outstanding voting capital
stock of the Company, which they may own, control or be entitled to vote,
determined on a fully diluted basis, and to take all necessary action within
their power to cause its nominees acting as officers or directors of the Company
to at all times act, in order that the provisions of this Agreement shall govern
the business and affairs of the Company to the maximum extent permitted by law.

                  (b) The Company, the Investors and the Prior Holders confirm
his, her or its knowledge of this Agreement and will carry out and be bound by
the provisions of this Agreement to the full extent that he, she or it has the
capacity and power at law to do so.

                  (c) Subject to the other provisions of this Agreement AND
NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THE BYLAWS OF THE COMPANY,
the Investors and the Prior Holders shall take all necessary action within their
power to ensure that the Company's Board of Directors shall consist of seven (7)
directors. The Investors and Prior Holders shall cause such meetings of the
Company to be held, votes cast, resolutions passed, bylaws enacted, documents
executed and things and acts done to ensure the election to the Company's Board
of Directors of the nominees as set out in Section 6.2(d) and Section 6.2(e).

                  (d) Subject to the prior nomination right of the
Debentureholders, the Investors and the Prior Holders shall take all necessary
action within their power to ensure that the Prior Holders shall have the right
to nominate the remaining directors, at their discretion, for such time that the
ownership of shares of Common Stock by the Prior Holders is at least 18% of the
outstanding shares of Common Stock on a fully-diluted basis. Without taking away
from the prior nomination right of the Debentureholders, if the ownership of
shares of Common Stock by the Prior Holders falls below 18% of the outstanding
shares of Common Stock on a fully-diluted basis, then the Prior Holders shall be
entitled to elect such number of directors as is determined by the following
formula: a percentage of the number of board members, rounded up to the nearest
whole number equal to the percentage of shares of Common Stock issued and held
by the Prior Holders bears to the total number of shares of Common Stock of the
Company then outstanding on a fully diluted basis. Any vacancy on the Board of
Directors of the Company after giving effect to the provisions of Sections
6.2(d) and 6.2(e) will be filled by individuals nominated by a majority of the
remaining directors then in office.

                  (e) The Investors and Prior Holders shall take all necessary
action within their power to ensure that the Debentureholders shall be entitled
to nominate the greater of (i) four (4) directors or (ii) such number of
directors as is determined by the following formula: a percentage of the number
of board members, rounded up to the nearest whole number equal to the percentage
of shares of Common Stock issued and held on a fully diluted basis, bears to the
total number of shares of Common Stock of the Company then outstanding on a
fully diluted basis. Notwithstanding the foregoing, in the event that all
outstanding indebtedness under the Convertible Debentures has been repaid by the
Company following a demand made by the Debentureholders pursuant to Section
2.7.1 of the Convertible Debentures, the Debentureholders shall lose their
rights pursuant to this Section 6.2(e) and all directors nominated by the
Debentureholders shall be required to immediately resign from the Company's

-27-
<PAGE>

Board of Directors. The vacancies caused by the resignation of the
Debentureholders' directors shall be filled by a majority of the Company's Board
of Directors and shall thereafter be elected by the holders of Common Stock and
Preferred Stock, voting together as a single class.

                  (f) The Investors and Prior Holders shall take all necessary
action within their power to ensure that the Debentureholders shall have the
right to have two (2) nominee directors appointed as members of both an Audit
Committee (comprised of three (3) members) and a Compensation Committee
(comprised of three (3) members). The remaining members of the Audit Committee
and the Compensation Committee will be determined by the Company's Board of
Directors.

                  (g) The Investors and Prior Holders shall take all such
necessary action within their power to ensure that the Debentureholders shall be
entitled to nominate one (1) representative who shall be permitted to attend at
and observe (but not vote at) any meeting of the Company's Board of Directors at
which at least one (1) director nominated by the Debentureholders cannot attend.
The Investors and Prior Holders shall take all such necessary action within
their power to ensure that such observer shall have the right to receive the
materials distributed to directors for meetings of the Company's Board of
Directors and to be heard at such meetings. The Investors and Prior Holders
shall take all such necessary action within their power to ensure that such
observer will be reimbursed for reasonable out-of-pocket expenses related to
attending meetings of the Company's Board of Directors. All information
furnished by the Company to the observer shall be treated as confidential
information, excluding only such information as is otherwise generally available
on a non-confidential basis. The observer shall use the standard of care to
maintain the confidentiality of all of the confidential information furnished by
the Company that is set out in Section 6.1(e) of this Agreement.

                  (h) Notwithstanding anything to the contrary contained in the
bylaws of the Company and subject to the limitations described Section 6.2(n),
the Company shall hold meetings of the Board of Directors after providing all
directors with at least five (5) calendar days' prior written notice; provided
that, upon the Debentureholders' request, if at least one (1) Debentureholder
nominee is unable or unwilling to attend any properly noticed meeting either in
person or telephonically, then the Company shall reschedule such meeting and
shall again provide at least five (5) calendar days' prior written notice.

                  (i) Meetings of the Board of Directors shall be held five (5)
times per year. Prior to the end of each fiscal year, the meetings of the Board
of Directors for the following fiscal year shall be scheduled. The timing of
four of the meetings shall coincide with the completion of each quarter for such
fiscal year, allowing sufficient time for the financial statements for such
quarter to be completed and circulated to the directors in advance of such
meeting. The fifth meeting shall be scheduled as a strategy/budget meeting for
the coming fiscal year. Materials for meetings of the Board of Directors shall
be provided to the directors at least 5 days prior to a meeting of the Board of
Directors.

                  (j) Meetings of the Audit Committee and the Compensation
Committee shall be scheduled prior to but on the same day as meetings of the
Board of Directors.

-28-
<PAGE>

                  (k) Each member of the Board of Directors shall be paid fees
of $12,500 per annum plus $4,000 per annum for each seat on the Audit Committee
or the Compensation Committee. Travel and accommodation expenses of the
directors and Committee members shall be for the account of the Company.

                  (l) The Company shall maintain directors and officers
insurance in scope and amount consistent with industry standards.

                  (m) The Company, the Investors and the Prior Holders agree
that, in addition to any fees paid by the Company pursuant to paragraph (k)
above, any services rendered by representatives of the Debentureholders in
favour of the Company or Occulogix, L.P. shall be compensated by the Company or
Occulogix, L.P., as the case may be, at fair market value and that all travel
and accommodation expenses associated with such services shall be paid by the
Company or Occulogix, L.P., as the case may be.

                  (n) Each notice of a meeting of the Board of Directors shall
set out in reasonable detail the business to be considered at such meeting and
no other business shall be transacted at such meeting without the consent of all
of the directors. Notwithstanding the notice periods described in Section 6.2(h)
above, in the event that the Chief Executive Officer and one other director or
any three directors of the Company determine that the Board of Directors needs
to act at a special meeting (a "Special Meeting") in order to respond to a
matter (other than the matters set forth in Section 6.2(o) of this Agreement)
with respect to which they determine in good faith that the failure of the Board
of Directors to immediately act would be potentially detrimental to the best
interests of the Company's stockholders, then such Special Meeting may be called
on forty-eight (48) hours prior notice. In the event that at least one (1)
Debentureholder nominee is unable to attend a Special Meeting either in person
or telephonically, the Company covenants that (i) it will take no action at such
Special Meeting that relates to that certain Limited Partnership Agreement of
OccuLogix, L.P., Sales Agreement, TLC Software License Agreement, VSC Software
License Agreement and License Agreement or adversely affects a Debentureholder,
in its capacity as a securityholder or joint venture partner with the Company
(or its affiliates) or otherwise or that affects a Debentureholder, in a
discriminatory manner inconsistent with its adverse effects of the rights of the
Company's other stockholders, and (ii) it will provide the Debentureholders with
prompt notice of any and all actions taken at such Special Meeting, including
providing the Debentureholders with any materials distributed to directors at
the Special Meeting.

                  (o) In addition to any other rights provided by law, the
Company shall not, without first obtaining the prior approval of the Board of
Directors (by vote at a properly noticed meeting in accordance with Section
6.2(h) of this Agreement or by unanimous written consent):

                        (i) authorize any stock option plans or other similar
contracts with stockholders, directors, officers, consultants and employees of
the Company for the purchase of securities of the Company or purchase any
key-person life insurance by the Company;

-29-
<PAGE>

                        (ii) take, hold, subscribe for or agree to purchase or
acquire shares of any corporation or take or have any interest in a joint
venture or partnership or similar undertaking;

                        (iii) approve the annual operating budget of the Company
and any material changes or alterations to such budget (including additional
expenditures not provided for therein);

                        (iv) incur indebtedness (other than payables in the
ordinary course of business) in excess of $100,000 in the aggregate;

                        (v) make any single capital expenditure in excess of
$10,000 per calendar month or aggregate capital expenditures in excess of
$25,000 per calendar month, unless included in a budget approved by the majority
of the Board of Directors;

                        (vi) acquire, or permit any subsidiary to acquire, any
interest in any business with a value in excess of $25,000 (whether by purchase
of assets, purchase of stock, merger or otherwise);

                        (vii) change the location of the Company's current head
office, executive office, principal place of business or jurisdiction of
incorporation;

                        (viii) change the fiscal year of the Company;

                        (ix) the appointment or change of the accountants or
auditors of the Company or change in accounting policies applied by the Company;

                        (x) the establishment of, or any change in the business
plan for the Company or senior management of the Company or entering into a
material strategic alliance, joint venture, material acquisition or disposition
or the carrying on by the Company of any other business or operation; or

                        (xi) enter into or modify any agreement, transaction or
arrangement with any of its officers, directors or employees, except for
customary compensation or benefit arrangements as approved by the majority of
Board of Directors.

                  (p) The Investors and Prior Holders covenant and agree to at
all times vote or cause to be voted all shares of outstanding voting capital
stock of the Company, which they may own, control or be entitled to vote,
determined on a fully diluted basis, and to take all necessary action within
their power to enable the Company to fulfill its obligations described in
Section 7.10 of the Series B Purchase Agreement, including, but not limited to,
voting in favor of any amendment to the Company's Certificate or Incorporation
necessary to effect such obligations.

                  (q) In addition to any other rights provided by law, the
Company shall not, without first obtaining the prior approval of the majority of
the Board of Directors of the Company, including at least one (1) nominee of the
Prior Holders, enter into any transaction with a party which does not deal at
arm's length with either of the Debentureholders where such

-30-
<PAGE>

transaction involves the transfer or sale of all or substantially all of the
assets of the Company or any merger, amalgamation or other business combination
with the Company.

                  (r) The Company and each of the Investors and Prior Holders
covenant and agree that they will take all necessary action to amend the bylaws
of the Company, as necessary, to implement and give effect to the provisions of
this Agreement.

            6.3 Board Designations.

            For purposes of this Agreement: (i) any individual who is designated
for election to the Company's Board of Directors pursuant to the foregoing
provisions of Section 6.2 is hereinafter referred to as a "Board Designee"; and
(ii) any individual, entity, or group of individuals and/or entities who has the
right to designate one or more Board Designees for election the Company's Board
of Directors pursuant to the foregoing provisions of Section 6.2 is hereinafter
referred to as a "Designator" or as "Designators," as applicable.

                  (a) NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THE
BYLAWS OF THE COMPANY, FROM time to time during the term of this Agreement, a
Designator or Designators shall, in their sole discretion, have the sole and
absolute right to:

                        (i) elect to or remove from the Company's Board of
Directors any incumbent Board Designee who occupies a Board seat for which such
Designator or Designators are entitled to designate the Board Designee under
Section 6.2; and/or

                        (ii) designate a new Board Designee for election to a
Board seat for which such Designator or Designators are entitled to designate
the Board Designee under Section 6.2 (whether to replace a prior Board Designee
or to fill a vacancy in such Board seat); provided, that, such removal and/or
designation of a Board Designee is approved in a writing signed by the
appropriate Designator or Designators who are entitled to designate such Board
Designee under Section 6.2, in which case such election to remove a Board
Designee and/or elect a new Board Designee will be binding on all such
Designators. In the event of such a removal and/or designation of a Board
Designee under this Section 6.3(a)(ii), the Investors and the Prior Holders
shall vote their shares of the Company's capital stock as provided in Section
6.2 to cause: (A) the removal from the Company's Board of Directors of the Board
Designee or Designees so designated for removal by the appropriate Designator or
Designators; and (B) the election to the Company's Board of Directors of any new
Board Designee or Designees so designated for election to the Company's Board of
Directors by the appropriate Designator or Designators.

                        (iii) Notwithstanding anything to the contrary in this
Section 6, if a Board Designee designated by the Prior Holders pursuant to
Section 6.2 who is an employee of the Company subsequently ceases to be an
employee of the Company, such Designee may be removed from the Company's Board
of Directors by the holders of a majority of the Common Stock held by the Prior
Holders determined on a fully diluted basis,. The vacancy on the Board of
Directors resulting from such removal shall be filled in the manner provided in
Section 6.2.

-31-
<PAGE>

                  (b) The Company shall promptly give each of the Investors and
the Prior Holders written notice of any change in composition of the Company's
Board of Directors and of any proposal by a Designator or Designators to remove
or elect a new Board Designee.

                  (c) Each of the Investors, the Prior Holders and the Company
agree not to vote any shares of Company capital stock, or to take any other
actions, that would in any manner defeat, impair, be inconsistent with or
adversely affect the stated intentions of the parties under this Section 6 of
this Agreement.

            6.4 Liquidity Covenant of Company.

                  If the Company:

                  (a) has not completed an Initial Public Offering and had its
common stock Listed prior to the date that is two years after the date that the
Company has received an "approvable ruling" for the Company's rheopheresis
technology from the U.S. Food and Drug Administration; or

                  (b) has recorded net income, calculated in accordance with
generally accepted accounting principles ("Net Income"), in excess of $1,000,000
in each of four consecutive fiscal quarters,

then the Board of Directors of the Company shall declare and shall cause the
Company to pay, on an annual basis, a dividend to holders of Common Stock, on a
fully-diluted basis, in an aggregate amount equal to 50% of Net Income. Such a
dividend shall be payable on an annual basis for such time as either condition
above continues to be satisfied.

            6.5 Except as set forth in this Section 6, the covenants set forth
in Section 6.3 shall terminate and be of no further force and effect after the
closing of the Qualified IPO.

      7.    Representations and Warranties.

            7.1 Each Prior Holder and Investor represents and warrants:

                  (a) that, subject to any transfers permitted hereunder, such
Prior Holder and Investor owns beneficially and of record the number of shares
of Common Stock (or any securities convertible or exchangeable or exercisable
into shares of Common Stock) which are expressed to be owned by him, her or it
in Schedule 7.1 to this Agreement, that such shares or securities are not
subject to any mortgage, lien, charge, pledge, encumbrance, security interest or
adverse claim and that no Person has any rights to become a holder or possessor
of any of such shares or of the certificates representing the same;

                  (b) that if such Prior Holder or Investor is an individual
that he or she has the capacity to enter into and give full effect to this
Agreement;

                  (c) that if such Prior Holder or Investor is a corporation,
that it is duly incorporated and validly existing under the laws of its
jurisdiction of incorporation and that it has the corporate power and capacity
to own its assets and to enter into and perform its obligations under this
Agreement;

-32-
<PAGE>

                  (d) if such Prior Holder or Investor is a trust, partnership
or joint venture, that it is duly constituted under the laws which govern it and
that it has the power to own its assets and to enter into and perform its
obligations under this Agreement;

                  (e) that this Agreement has been duly authorized by it, and
duly executed and delivered by him, her or it, as the case may be, and
constitutes a valid and binding obligation enforceable in accordance with its
terms, subject to the usual exceptions as to bankruptcy and the availability of
equitable remedies;

                  (f) that the execution, deliver and performance of this
Agreement does not and will not contravene the provisions of its articles,
bylaws, constating documents or other organizational documents or the documents
by which it was created or established or the provisions of any indenture,
agreement or other instrument to which he or it is a party or by which he or it
may be bound; and

                  (g) that all of the foregoing representations and warranties
will continue to be true and correct during the continuance of the Agreement.

            7.2 The Company, to the best of its knowledge, information and
belief confirms the representations and warranties set out in Section 7.1 and
further represents and warrants that the securities set forth in Schedule 7.1
are the only outstanding securities of the Company.

      8.    Miscellaneous.

            8.1 SUCCESSORS AND ASSIGNS. Except as otherwise provided in this
Agreement, the terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective successors and assigns of the parties
(including transferees of any Registrable Securities). Nothing in this
Agreement, express or implied, is intended to confer upon any party other than
the parties to this Agreement or their respective successors and assigns any
rights, remedies, obligations, or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement.

            8.2 GOVERNING LAW. This Agreement shall be governed by and construed
exclusively in accordance with the internal laws of the State of Delaware,
without giving effect to any choice of law or conflict of law provisions.

            8.3 COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original and all of which
taken together shall be deemed to constitute one and the same instrument.
Counterparts may be executed either in original or faxed form and the parties
adopt any signatures received by a receiving fax machine as original signatures
of the parties.

            8.4 TITLES AND SUBTITLES. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

            8.5 NOTICES. Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed
effectively given (i) upon personal delivery to the party to be notified; (ii)
upon transmission, when sent by facsimile if sent during normal business hours
of the recipient, if not, then on the next business day; (iii) five calendar
days after having been sent by registered or certified mail, return receipt
requested,

-33-
<PAGE>

postage prepaid; (iv) one day after a deposit with a nationally recognized
overnight courier, specifying next day delivery, with written verification of
receipt. All communications shall be sent to the address indicated for such
party on the signature page hereof, or at such other address as such party may
designate by ten (10) calendar days advance written notice to the other parties.

            8.6 SEVERABILITY. If one or more provisions of this Agreement are
held to be unenforceable under applicable law, then such provision(s) shall be
excluded from this Agreement and the balance of this Agreement shall be
interpreted as if such provision(s) were so excluded and shall be enforceable in
accordance with its terms.

            8.7 THIRD PARTIES. Nothing in this Agreement, express or implied, is
intended to confer upon any Person, other than the parties hereto and their
successors and assigns, any rights or remedies under or by reason of this
Agreement.

            8.8 ENTIRE AGREEMENT. This Agreement, together with all the exhibits
hereto, constitutes and contains the entire agreement and understanding of the
parties with respect to the subject matter of this Agreement and supersedes any
and all prior negotiations, correspondence, agreements, understandings, duties
or obligations between the parties respecting the subject matter of this
Agreement.

            8.9 COSTS AND ATTORNEYS' FEES. In the event that any action, suit or
other proceeding is instituted concerning or arising out of this Agreement or
any transaction contemplated hereunder, the prevailing party shall recover all
of such party's costs and attorneys' fees incurred in each such action, suit or
other proceeding, including any and all appeals or petitions therefrom.

            8.10 ADJUSTMENTS FOR STOCK SPLITS AND CERTAIN OTHER CHANGES.
Wherever in this Agreement there is a reference to a specific number of shares
of Common Stock or Preferred Stock of the Company of any class or series, then,
upon the occurrence of any subdivision, combination or stock dividend of such
class or series of stock, the specific number of shares so referenced in this
Agreement shall automatically be proportionally adjusted to reflect the effect
on the outstanding shares of such class or series of stock by such subdivision,
combination or stock dividend.

            8.11 AGGREGATION OF STOCK. All shares held or acquired by affiliated
entities or persons shall be aggregated together for the purpose of determining
the availability of any rights under this Agreement.

            8.12 GENERALLY ACCEPTED ACCOUNTING PRINCIPLES. Wherever in this
Agreement, or any Exhibit hereto, reference is made to a calculation to be made
or an action to be taken in accordance with generally accepted accounting
principles, such reference will be deemed to be to the generally accepted
accounting principles from time to time by the American Institute of Certified
Public Accountants or any successor institute, applicable as at the date on
which such calculation or action is made or taken or required to be made or
taken in accordance with generally accepted accounting principles.

            8.13 COOPERATION. The parties shall cooperate fully in good faith
with each other and their respective legal advisers, accountants and other
representatives in connection with any steps required to be taken as part of
their respective obligations under this Agreement.

            8.14 REMEDIES CUMULATIVE. The rights and remedies of the parties
under this Agreement are cumulative and in addition to and not in substitution
for any of the rights or remedies provided by law. Any single or partial
exercise by any party hereto of any right or remedy for default or breach of any
term, covenant or condition of this Agreement does not

-34-
<PAGE>

waive, alter, affect or prejudice any other right or remedy to which such party
may be lawfully entitled for the same default or breach.

            8.15 TIME OF ESSENCE. Time shall be of the essence of this
Agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Investors' Rights
Agreement as of the date first set forth above.

                                        "THE COMPANY":
                                        VASCULAR SCIENCES CORPORATION

                                        By:______________________________
                                           Richard Davis, Jr., M.D,
                                           President and Chief Executive Officer

                                        Address: 612 Florida Avenue
                                                 Palm Harbor, FL 34683
                                                 Attention: President
                                                 Fax: (727) 784-0898

-35-
<PAGE>

                         COUNTERPART SIGNATURE PAGE TO
                         VASCULAR SCIENCES CORPORATION
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT
                                   "INVESTORS"

                                          Diamed Medizintechnik GMBH

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          TLC Vision Corporation

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

<PAGE>

                                          ______________________________________
                                          Howard Howell

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Rehab Associates of West Florida, P.A.

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          Charles Edgar Hart

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-ii-
<PAGE>

                                          ______________________________________
                                          Charles Edgar Hart Jr.

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Nancy E. Hart

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Patrick J. Sheppard

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Stephen M. Weinstock

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-iii-
<PAGE>

                                          ______________________________________
                                          David Hooks

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Barkley Family Partnership, Ltd.

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          Roger and S. Lorraine C. Golomb

                                          ______________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-iv-
<PAGE>

                                          Gene DMD and Brenda Whitehead

                                          ______________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Jeffrey S. Schwartz and S. Maribeth
                                          Turner

                                          ______________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-v-
<PAGE>

                                          William J. Jr. MD and Kris Richards

                                          ______________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Richard J. Hairston

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Gary M. Najar

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-vi-
<PAGE>

                                          Northlea Partners

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          Michael O. and Rebecca L. Abdoney

                                          ______________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Alan B. Aker

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-vii-
<PAGE>

                                          The Thomas D. Arthur Revocable Trust

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          Richard Beard, III

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-viii-
<PAGE>

                                          ______________________________________
                                          Daniel A. Bertoch, D.D.S.

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Brandt, Tom E.

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          David C. Brown

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-ix-
<PAGE>

                                          Capital Paradigms, Inc.

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          Margaret A. Cornish

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-x-
<PAGE>

                                          DD Irrevocable Trust, Nancie Reichle,
                                          Trustee

                                          By:___________________________________
                                             Nancy Reichle, Trustee

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          David W. Dieters

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Raphael Andre Drehsen

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xi-
<PAGE>

                                          Dan and Lockye Drone

                                          ______________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Dubin, Richard J.

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Burt W. Dubow

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xii-
<PAGE>

                                          Richard and Brigitte Fielder, JT TEN

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          First Trust Corporation TTEE FBO
                                          David H. Shapiro Acct # 031038028709

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

-xiii-
<PAGE>

                                          Gills, James P. Gills Flint Trust
                                          Dated 12/20/99

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          David E. Geller

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Willi E. Gunti

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xiv-
<PAGE>

                                          ______________________________________
                                          Cecil S. Harrell

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          JTB VisionQuest Corporation

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          William S. Jacobson

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xv-
<PAGE>

                                          Charles S. and Edeltrout Jenkins

                                          ______________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Dan R. Johnson, Revocable Trust

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          Ralph Katz

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xvi-
<PAGE>

                                          ______________________________________
                                          Greta Meeks

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Lorraine K. Mikolon

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Gregory Mincey

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xvii-
<PAGE>

                                          Anthony P. Pizzo Family Trust

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          Richard Powell

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Dr. John A. Retzlaff

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xviii-
<PAGE>

                                          ______________________________________
                                          A.H. Rodriguez

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          A.H. Rodriguez Family Trust

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          A.H. or Christopher Rodriguez

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Donna Rodriguez Family Trust

-xix-
<PAGE>

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          Jennifer or Donna Rodriguez

                                          ______________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Eric F. Rubin

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xx-
<PAGE>

                                          ______________________________________
                                          Leslie A. Rubin

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Tracie B. Rubin

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Safe Harbor Fund I, L.P.

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

-xxi-
<PAGE>

                                          Safe Harbor Managed Account 101-A,
                                          Ltd.

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          Donald Sanders, Custodian for Kendra
                                          Sanders

                                          By:___________________________________
                                             Donald Sanders, Custodian

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Date:___________________________, 2003

-xxii-
<PAGE>

                                          Donald Sanders, Custodian for Monica
                                          Sanders

                                          By:___________________________________
                                             Donald Sanders, Custodian

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Date:___________________________, 2003

                                          Donald Sanders, IRA CIBC
                                          Oppenheimer as Custodian

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          Santaromita, Joseph

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          The Schoenbaum Revocable Trust dtd
                                          10/29/99

-xxiii-
<PAGE>

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          Chris Spieldenner

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Mark Stern and Ellen Kaplan Stern,
                                          ATBE

                                          ______________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Mark Stern and Ellen Kaplan Stern,
                                          Irrevocable Trust for Elliott Benjamin
                                          Stern

                                          By:___________________________________

-xxiv-
<PAGE>

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          Mark Stern and Ellen Kaplan Stern,
                                          Irrevocable Trust for Lennie Beth
                                          Stern

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

-xxv-
<PAGE>

                                          Mark Stern and Ellen Kaplan Stern,
                                          Irrevocable Trust for Zachary Adam
                                          Stern

                                          By:___________________________________

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Name:_________________________________

                                          Title:________________________________

                                          Date:___________________________, 2003

                                          ______________________________________
                                          Elizabeth Strapp

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Alan Szucs

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xxvi-
<PAGE>

                                          ______________________________________
                                          David E. Wise

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Ellis Wolben

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Thomas G. Wolf

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xxvii-
<PAGE>

                                          ______________________________________
                                          Richard C. Davis, Jr.

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          ______________________________________
                                          Hans K. Stock

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-xxviii-
<PAGE>

                         COUNTERPART SIGNATURE PAGE TO
                         VASCULAR SCIENCES CORPORATION
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT
                                "PRIOR HOLDERS":

                                          Richard C. Davis, Jr.

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Hans K. Stock

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Jane Cornish Smith

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Ramia H. Cornish

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

<PAGE>

                                          ______________________________________

                                          John Cornish

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

                                          Margaret A. Cornish QDOT Trust,
                                          dated 8/2/90, Margaret A. Cornish and
                                          Jane Cornish Smith, Trustees

                                          By:___________________________________
                                             Margaret A. Cornish, Trustee

                                          By:___________________________________
                                          Jane Cornish Smith , Trustee

                                          Address:______________________________
                                          ______________________________________
                                          ______________________________________

-ii-
<PAGE>

                                   Schedule A

                    SCHEDULE OF INVESTORS AND THEIR HOLDINGS

<TABLE>
<CAPTION>
                                                                                   SHARES OF
                                                                                  COMMON STOCK
                                                        SHARES OF  SHARES OF        ISSUABLE
                                         SHARES OF      SERIES A    SERIES B       PURSUANT TO
                                          COMMON       PREFERRED   PREFERRED       CONVERTIBLE
          INVESTOR                         STOCK         STOCK       STOCK         DEBENTURES
<S>                                      <C>           <C>         <C>          <C>
Diamed Medizintechnik GMBH                 125,000        191,493                      3,553,226

TLC Vision Corporation                                               524,070           3,553,226

Howell, Howard                                                        22,964

Rehab Associates of West Florida, P.A.                                 4,875

Hart, Charles Edgar                                                      975

Hart, Edgar Hart Jr.                                                     975

Hart, Nancy E.                                                           975

Sheppard, Patrick J.                                                   9,751

Weinstock, Stephen M.                                                  5,850

Hooks, David                                                           7,801

Barkley Family Partnership, Ltd.                                       7,313

Golomb, Roger, S. Lorraine C.                                          4,875

Whitehead, Gene DMD, Brenda                                            4,875

Schwartz, Jeffrey S. Maribeth Turner-                                  2,925

Richards, William J. Jr. MD, Kris                                      3,900

Hairston, Richard J.                                                   3,900

Najar, Gary M.                                                         4,875

Northlea Partners                                           3,821      3,900

Abdoney, Michael O. and Rebecca L.           3,125          3,648

Aker, Alan B.                                             205,499

The Thomas D. Arthur Revocable Trust         6,250          7,295

Beard, Richard, III                                         3,648

Bertoch, Daniel A., D.D.S.                                  3,648
</TABLE>

<PAGE>

<TABLE>
<S>                                                <C>            <C>            <C>
Brandt, Tom E.                                                    14,591

Brown, David C.                                                   65,760

Capital Paradigms, Inc.                                              486

Cornish, Margaret A.                                               3,648

Davis, Richard C., Jr.                                            79,751

Dieters, David W.                                                  2,918

Drehsen, Raphael Andre                                               912

Drone, Dan and Lockye                                6,250

Dubin, Richard J.                                                  1,824

Dubow, Burt W.                                                     5,218

Fielder, Richard and Brigitte, JT TEN               75,700         7,295

First Trust Corporation TTEE FBO                                                 4,875
David H. Shapiro Acct # 031038028709

Gills, James P. Gills Flint Trust Dated 12/20/99   187,500        42,223

Geller, David E.                                     3,750         3,648

Gunti, Willy E.                                     25,000

Harrell, Cecil S.                                    6,250         7,295

JTB VisionQuest Corporation                                          989

Jacobson, William S.                                               3,288

Jenkins, Charles S. and Edeltrout                    1,562         1,824

Johnson, Dan R. Revocable Trust                      6,250         3,648

Kahn, Harvey                                                       3,288

Katz, Ralph                                                        3,288

Meeks, Greta                                                       1,824

Mikolon, Lorraine K.                                                 822

Mincey, Gregory                                                    8,220

Pizzo, Anthony P. Family Trust                                     3,648

Powell, Richard                                                    7,295

RD Irrevocable Trust, Reichle, Nancie, Trustee                    12,527

Retzlaff, Dr. John A.                                             32,880
</TABLE>

- ii -

<PAGE>

<TABLE>
<S>                                               <C>          <C>               <C>        <C>
Rodriguez, A.H.                                                    4,008             438

Rodriguez, A.H. Family Trust                                      40,125

Rodriguez, A.H. or Christopher                                     3,648

Rodriguez, Donna Family Trust                                     40,125

Rodriguez, Jennifer or Donna                                       3,648

Rubin, Eric F.                                                     1,824

Rubin, Leslie A.                                                   3,648

Rubin, Tracie B.                                                   1,824

Safe Harbor Fund I, L.P.                                          13,883

Safe Harbor Managed Account 101-A, Ltd.                           21,082

Sanders, Donald, Custodian for Kendra Sanders                      9,098

Sanders, Donald, Custodian for Monica Sanders                      9,098

Sanders, Donald, IRA CIBC                          250,000       246,599
Oppenheimer as Custodian

Santaromita, Joseph                                                2,466

The Schoenbaum Revocable Trust dtd 10/29/99                        7,295

Spieldenner, Chris                                                 7,295

Stern, Mark and Ellen Kaplan Stern, ATBE            80,548        14,591

Stern, Mark and Ellen Kaplan Stern,                                  730
Irrevocable Trust for Elliott Benjamin Stern

Stern, Mark and Ellen Kaplan Stern,                                  730
Irrevocable Trust for Lennie Beth Stern

Stern, Mark and Ellen Kaplan Stern,                                  730
Irrevocable Trust for Zachary Adam Stern

Stock, Hans                                                       72,954

Strapp, Elizabeth                                                    912

Szucs, Alan                                          3,125         3,648

Wise, David E.                                                    20,550

Wolbe Ellis                                                        3,648

Wolf, Thomas G.                                      3,125         3,648

TOTALS                                             783,435     1,275,932         620,112    7,106,452
</TABLE>

- iii -

<PAGE>

                                   Schedule B

                                  PRIOR HOLDERS

<TABLE>
<CAPTION>
                 NAME OF PRIOR HOLDERS                NUMBER OF SHARES OF COMMON STOCK HELD
----------------------------------------------------  -------------------------------------
<S>                                                   <C>
Richard C. Davis, Jr.                                                1,184,603
Hans K Stock                                                           250,000
John Cornish                                                           228,589
Jane Cornish Smith                                                     230,586
Ramia H. Cornish                                                       206,250
Margaret A. Cornish QDOT Trust, dated 8/2/90,                          676,676
Margaret A. Cornish and Jane Cornish Smith, Trustees
TOTAL:                                                               2,776,704
</TABLE>

- iv -

<PAGE>

                                  Schedule 7.1

                             OUTSTANDING SECURITIES

-v-<PAGE>

                                                                    EXHIBIT 10.1

                      ASSIGNMENT AND DISTRIBUTION AGREEMENT

      THIS ASSIGNMENT AND DISTRIBUTORSHIP AGREEMENT (the "Agreement") is entered
into as of March 22, 2000, by and among RheoLogix, L.L.C., a Delaware limited
liability company ("RheoLogix"), Apheresis Technologies, Inc., a Florida
corporation ("ATI") ("RheoLogix and ATI are sometimes collectively referred to
as the "Assignor") and CytaLogix Corporation, a Delaware corporation
("Assignee").

                                    RECITALS

      A. Assignor is the holder, owner and possessor of certain rights,
technologies, devices, know-how, proprietary information, clinical data,
intellectual property, and other unique and valuable assets, tangible and
intangible, which are useful in providing extracorporeal blood
separation/filtering procedures, including, without limitation, rights under the
Asahi Distributorship Agreement (as defined herein) and certain rights granted
by the Unites States Food and Drug Administration and the United States Patent
Office (the foregoing and any and all anticipated an unanticipated future rights
of Assignor relating to the Foregoing are, collectively, the "Proprietary Rights
and Technologies").

      B. Contemporaneously with the assignment of the Assigned rights and
Technologies (as defined herein) hereunder, Assignor will assign certain of the
Proprietary Rights and Technologies similar to the Assigned Rights and
Technologies to certain of its affiliates, including, without limitation, (i)
OccuLogix Corporation, a Florida corporation ("OccuLogix"); (ii) VascuLogix
Corporation, a Delaware corporation ("VascuLogix"); and (iii) NephroLogix
Corporation, a Delaware corporation ("NephroLogix"); provided that, Assignor may
assign rights similar to the Assigned Rights and Technologies to other
companies, entities, and individuals.

      C. Assignor desires to assign, and Assignee desires to accept, in
accordance with and pursuant to the terms herein, the Assigned Rights and
Technologies.

                                    COVENANTS

      In consideration of the mutual covenants and promises hereinafter set
forth, and other good and valuable consideration, the sufficiency of which is
hereby acknowledged, the parties hereto agree as follows:

1. ASSIGNMENT. Assignor hereby assigns to Assignee, its successors and assigns,
and Assignee, its successors and assigns, hereby accepts, an exclusive right to
use, sell, market, develop or distribute the Assigned Rights and Technologies
specifically for use within the Market (as defined herein).

      1.1 ASSIGNED RIGHTS AND TECHNOLOGIES. Whenever used herein, "Assigned
Rights and Technologies" shall mean the Proprietary Rights and Technologies, and
any and all anticipated and unanticipated future rights, including, without
limitation, certain rights granted by the United States Food and Drug
Administration, Assignor may acquire, purchase, procure,

<PAGE>

develop, receive, accept or otherwise obtain in connection with the Proprietary
Rights and Technologies.

      1.2 MARKET. Whenever used herein, "Market" shall mean any and all
treatment and/or research relating to the Disease (as defined herein) performed
and/or conducted in the Territory (as defined herein).

      1.3 DISEASE. Whenever used herein, "Disease" shall mean any and all
cell-mediated chronic inflammatory diseases, specifically, without limitation,
Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis and Multiple
Sclerosis.

      1.4 TERRITORY. Whenever used herein, "Territory" shall mean and any and
all present and future territories held, owned or possessed by Assignor relating
to the Assigned Rights and Technologies (currently the United States, Canada,
and Mexico).

2. LIMITATION OF CERTAIN OF THE ASSIGNED RIGHTS AND TECHNOLOGIES. In addition to
the limitations upon the commercial application, scope an utility of the
Assigned rights and Technologies contained herein, Assignee acknowledges and
understands that certain of the Assigned Rights and Technologies are now and may
continue to be effectively limited in their commercial application, scope and
utility by certain agreements, licenses and other obligations, including,
without limitation, (i) the limitations upon the use, sale, marketing,
development and distribution of the Device (as defined herein) contained in that
certain 1997 Distributorship Agreement, by and between Asahi Medical Co., Ltd.,
a corporation organized and existing under the laws of Japan ("Asahi") and ATI,
dated February 1, 1997, as amended by that certain Amendment to 1997
Distributorship Agreement and Plasmaflo Agreement, by and between Asahi and ATI,
dated January 1, 1999, as amended (collectively, the "Asahi Distributorship
Agreement"), and (ii) any and all other instruments, assignments, documents
and/or agreements pursuant to which Assignor obtains the right to distribute
some or all of the Assigned rights and Technologies.

3. MARKET. Assignee acknowledges, accepts and understands that Assignor,
contemporaneously herewith will, and in the future may, assign rights in the
Proprietary rights and Technologies for use outside of the Market to third
parties or other assignees, including, without limitation, OccuLogix,
VascuLogix, and NephroLogix, which are similar to the rights in the Assigned
Rights and Technologies assigned hereunder (provided that Assignor shall not
assign rights in the Proprietary Rights and Technologies for use within the
Market which are similar to the rights in the Assignor Rights and Technologies
assigned hereunder). Assignee agrees that it will not, directly or indirectly,
whether through or by one of its affiliates or otherwise, use, sell, market,
develop or distribute the Assigned Rights and Technologies outside of the
Market. In the event a dispute arises among Assignee and any or all of
OccuLogix, VascuLogix and NephroLogix as to the ownership and/or commercial
application of the Proprietary Rights and Technologies, including, without
limitation, the scope of a specific Market, Disease, or Territory (as such terms
are defined in the individual assignments from Assignor to each of Assignee,
OccuLogix, VascuLogix and NephroLogix), then Assignor shall act as the sole
arbiter and shall provide an equitable determination of the ownership and/or
commercial application of the Proprietary Rights and Technologies among the
parties. Assignee

                                       -2-
<PAGE>

hereby agrees to be bound by such determination(s) made by Assignor and to fully
comply with the terms of such determination(s).

4. RIGHT OF ASSIGNEE TO ASSIGN THE ASSIGNED RIGHTS AND TECHNOLOGIES. Assignee
shall have the right to assign any or all of its right and interest in the
Assigned Rights and Technologies to third parties or its affiliates, provided,
that, the terms and provisions of any such assignment shall (i) be substantially
similar to, and no less favorable to Assignor than, the terms and provisions of
this Agreement, including, without limitation, the restrictions on the use,
sale, marketing, development and distribution of the Assigned Rights and
Technologies and (ii) not conflict with the Asahi Distributorship Agreement.

5. AGREEMENT TO SUPPLY CERTAIN OF THE ASSIGNED RIGHTS AND TECHNOLOGIES.

      5.1 EXCLUSIVE DISTRIBUTORSHIP. As a part of the assignment of the Assigned
Rights and Technologies hereunder, ATI shall grant to Assignee (i) the exclusive
right to use, sell, market, develop or distribute the products set forth in
Exhibit A attached hereto for use within the Market ("Product I") and (ii) the
non-exclusive right to use, sell, market, develop or distribute the products set
forth on Exhibit B attached hereto for use within the Market ("Product II")
(Product I and Product II are collectively, the "Device"), and Assignee (y)
agrees to give Assignor the first opportunity to fill any orders for the Device
pursuant to his Agreement, and (z) subject to Section 5.6.2, agrees not to
purchase, use, sell, market, develop or distribute any apheresis devices or
similar devices other than the Device, without the prior written consent of
Assignor.

      5.2 SALE OF DEVICE AT COST; PAYMENT TERMS.

            5.2.1 ATI shall sell the Device to Assignee at Cost. Whenever used
      herein, "Cost" shall mean the aggregate price paid by ATI for the Device,
      including all transfer costs, shipping, import duties, royalties and the
      price paid to Asahi for the Device, less any discounts or allowances.

            5.2.2 Unless otherwise agreed in writing by Assignor and Assignee,
      upon Assignee's receipt of ATI's acceptance of an order by Assignee,
      Assignee (i) shall open an irrevocable letter of credit ("L/C") within
      thirty (30) days after bill of lading date in favor of ATI for the Cost of
      such order or (ii) shall make the advanced payment for the Cost of such
      order by money transfer in favor of ATI to ATI's designated account. Any
      bank charges related to the opening or amendment of the L/C or advanced
      payment shall be borne by Assignee.

      5.3 SCHEDULE OF ORDERS FOR THE DEVICE. For the purpose of sales planning
by ATI, Assignee shall submit to ATI, in writing, before the tenth (10th) day of
each calendar quarter, a report of Assignee's sales and inventory of the Device,
including the level of inventory of the Device by article. Assignee also shall
submit to ATI, upon request from time to time, information in its possession
with respect to competitors' state of marketing and general market information,
relevant economic, political and business conditions in the Territory, and texts
and summaries of governmental statutes, rules and regulations established or
revised from time to time, affecting the marketing or sale of the Device in the
Territory.

                                      -3-
<PAGE>

      5.4 MONTHLY FORECASTS. Assignee shall submit to ATI a monthly rolling
order forecast before the fifteenth (15th) day of each calendar month for the
six (6) calendar month period immediately following such calendar month. The
rolling order forecasts for the first two (2) months of each such six (6) month
period shall be deemed a firm order for the Device, and each monthly forecast
shall be consistent with previous forecasts with respect to such firm orders.

      5.5 ACCEPTANCE OF ORDERS. Assignee's order shall be deemed accepted when
it is acknowledged and accepted by ATI in writing which shall include, without
limitation, transmission via facsimile or email. Assignee may not cancel any
order after it is accepted by ATI without the written consent of ATI.

      5.6 BEST EFFORTS FOR DELIVERY; DELAY IN DELIVERY; APPORTIONMENT.

            5.6.1 ATI shall use its best efforts to deliver the Device in
      accordance with the delivery schedules set forth in the accepted orders.
      ATI shall promptly notify Assignee if it anticipates any potential delay.

            5.6.2 If Assignee has given Assignor reasonable time to fill an
      order of the Device and if ATI, in the reasonable judgment of Assignee,
      has not or will not be able to completely or partially fill orders
      accepted by ATI in accordance with Section 5.5, then (i) Assignee, at its
      discretion and upon the giving of written notice to Assignor, may agree to
      accept a delayed or partial shipment of the Device or (ii) Assignee, at
      its discretion and upon the giving of written notice to Assignor, may fill
      all or a portion of its unfilled order for the Device directly from Asahi
      and/or any other distributor. Notwithstanding the foregoing, the rights of
      Assignee provided for in this Section 5.6.2 shall not relieve Assignee of
      its obligation to give Assignor the first opportunity to fill any
      subsequent orders for the Device.

            5.6.3 In the event that Assignee, after first attempting to fill an
      order of the Device with Assignor, fills all or a portion of an order of
      the Device directly from Asahi and/or another distributor in accordance
      with Section 5.6.2, then, upon written notice from Assignee of Assignee's
      intention to seek other distributors to fill all or a portion of its
      order, Assignor shall immediately refund to Assignee any and all portions
      of an advanced payment for which Assignee has not or will not receive
      Devices. The portion of such order relating to Devices for which Assignee
      will seek delivery from a distributor other than Assignor will be deemed
      canceled in all respects and neither Assignor nor Assignee shall have any
      further obligation relating to such canceled portion of the order, other
      than Assignor's obligation to immediately refund to Assignee any advance
      payment by Assignee.

            5.6.4 In the event that ATI is unable to fill all of the orders
      placed at a specific time by each of Assignee, OccuLogix, VascuLogix and
      NephroLogix (for purposes of this Section 5.6.4, collectively, the
      "Orderers"), then ATI agrees to equitably and reasonably apportion its
      Devices on-hand among the Orderers; provided, that, any or all of the
      Orders may seek to fill the unfilled portion of its order through Asahi
      directly or any other distributor in accordance with Section 5.6.2

                                      -4-
<PAGE>

      5.7 TERMS OF DELIVERY. The delivery of the Device shall be at the office
of Assignee or such other place as reasonably requested by Assignee. ATI shall
have the sole responsibility for the delivery of the Device to such destination.
Assignee, in accordance with Section 5.2.1, shall be responsible for all
expenses in connection with the delivery and shipment of the Device, including,
without limitation, all expenses incurred in the storage, cartage and
transportation of the Device, as well as all insurance, fees, charges, taxes
(whether sales, use, value added or other), and governmental charges or levies
and all other charges or levies relating to the delivery of the Device, whether
the same are levied upon Assignor or Assignee.

      5.8 RISK OF LOSS AND TITLE. The title to and risk of loss of the Device
shall pass from ATI to Assignee at the time when the purchased Device have been
delivered to Assignee, to another person acting on Assignee's behalf or to such
other place as reasonably requested by Assignee. All risks of loss in connection
with the Device thereafter shall rest upon Assignee, including, without
limitation, all risks incurred in the storage, cartage and transportation of the
Device. ATI shall not be deemed in anyway responsible for obtaining freight
and/or insurance, and shall not in any way be liable for the transportation,
cartage, insurance or other aspects of the storage or shipment of the Device,
after passage of title thereto to Assignee as set forth above.

      5.9 WARRANTY.

            5.9.1 If any Device is in a damaged condition upon its delivery to
      Assignee, or the amount delivered is less than that provided for in the
      order accepted by ATI, Assignee shall advise ATI in writing of any such
      circumstance within six (6) months of delivery of such Device and shall
      fully describe the nature of the shortage or damage. ATI shall replace
      such damaged Device and/or remedy such shortages, without additional
      charge; provided, that, ATI is given the notice referred to above and the
      opportunity promptly to inspect the claimed damaged or incompletely
      delivered Device, and provided further that ATI is reasonably satisfied
      that such damage and/or shortage was not caused by mishandling or misuse
      by the parties other than ATI after title passed to Assignee. In the event
      that Assignee fails to notify ATI or allow such inspection as described
      above, Assignee shall be deemed to have waived all damage and shortage
      claims against ATI for said Device.

            5.9.2 Assignor warrants that the Device has been manufactured and
      distributed in compliance with the United States Food and Drug
      Administration "good manufacturing practices." Other than the foregoing
      warranty, Assignor makes no warranty as to the manufacture or distribution
      of the Device. The Device shall be subject only to the applicable warranty
      provided by the manufacturer and Assignor will have no responsibility
      therefor; and provided further that all warranties described above in this
      Section 5.9.2 shall be ineffective, and Assignor shall have no
      responsibility whatsoever, in the event any Device has been subjected to
      misuse, mishandling, misapplication, neglect, contamination, accident,
      improper repair, damage by circumstances beyond Assignor's reasonable
      control or unauthorized modification by Assignee or its immediate
      customers, including, without limitation, any damage, contamination,
      defects or malfunctions resulting from (a) the opening of the packaging of
      the Device to combine the bloodline to be procured by Assignee and to be
      used for the Device, (b) the repackaging of the Device with the bloodline
      for delivery to customers, or (c) the failure

                                      -5-
<PAGE>

      to adhere to instructions for use and other documentation included in
      shipments of the Device. The responsibility of Assignor under all
      warranties is limited solely to the repair or replacement of the Device,
      as the case may be, pursuant to the foregoing warranties. All warranty
      claims are subject to verification by Assignor.

            5.9.3 THE WARRANTIES SET FORTH ABOVE ARE EXCLUSIVE AND IN LIEU OF,
      AND ASSIGNOR EXPRESSLY DISCLAIMS, ALL OTHER WARRANTIES, EXPRESS OR
      IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABLITY OR
      FITNESS FOR A PARTICULAR USE OR PURPOSE AND THOSE ARISING BY STATUTE OR
      OTHERWISE IN LAW OR FROM A COURSE OF DEALING OR USE OF TRADE. ASSIGNOR
      SHALL NOT HAVE ANY LIABILITY TO ASSIGNEE, ITS CUSTOMERS, END-USERS OR ANY
      OTHER PARTY OR ANY AMOUNTS IN EXCESS OF THE ORDER PRICE OF THE DEVICE NOR
      FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT
      LIMITATION, LOST PROFITS OR PROSPECTIVE PROFITS OR ANY OTHER COMMERCIAL OR
      ECONOMIC LOSS OF ANY KIND OR NATURE OF ASSIGNEE OR ANY THIRD PERSON, EVEN
      IF ASSIGNOR HAS BEEN ADVISED OF THE POSSIBILITY OF THE SAME, ARISING OUT
      OF OR IN CONNECTION WITH THE USE OR PERFORMANCE OF THE DEVICE.

            5.9.4 Assignee shall not represent, in relation to the Device
      purchased hereunder, to its customers any warranties of any nature
      whatsoever other than those given by Assignor or required by applicable
      law.

      5.10 TRADEMARK AND OTHER RIGHTS.

            5.10.1 Assignee shall use the trademark(s) designated by Asahi
      (hereinafter referred to as "Trademark"), including, without limitation,
      "Plasmaflo," "Hemosorba" and "Rheofilter," as instructed by Assignor in
      distributing the Device purchased hereunder and shall not use any other
      trademarks in connection with such distribution without prior written
      consent of Assignor. Assignee acknowledges that Asahi is the owner of all
      right, title and interest in and to the Trademark in the Territory in any
      form or embodiment thereof and is the owner of the goodwill attached or
      which shall become attached to the Trademark in connection with the
      business and goods in relation to which the same has been, is or shall be
      used. Sales by Assignee shall be deemed to have been made by Asahi for
      purposes of trademark registration and all uses of the Trademark by
      Assignee shall inure to the benefit of Asahi. Assignee shall not, at any
      time, do or suffer to be done any act or thing which may in any way
      adversely affect any rights of Asahi in and to the Trademark or any
      registration thereof or which, directly or indirectly, may reduce the
      value of the Trademark or detract from its reputation. At Assignor's
      request, Assignee shall execute any documents, including registered user
      agreements, reasonably required by Assignor to confirm Asahi's ownership
      of all rights in and to the Trademark in the Territory and to confirm the
      respective rights of Assignor and Assignee under this Agreement. Assignee
      shall not alter, obliterate, deface or remove any mark, marking, serial
      number or other symbol carried on the Device or on the packaging in which
      the Device are enclosed without the consent of Assignor. In the event that
      Asahi desires to

                                      -6-
<PAGE>

      change any such mark, marking, serial number of other symbol, Assignee
      will cooperate with Assignor in such manner as may be agreed upon by the
      parties. Assignee never shall challenge Asahi's ownership of or the
      validity of the Trademark or any application for registration there, or
      any trademark registrations thereof, or any rights of Asahi's therein.

            5.10.2 During the term of this Agreement and thereafter, Assignee
      shall not apply for or acquire the registration of the Trademark, not
      shall Assignee contest Asahi's right in or disturb Asahi's use of the
      trademark or goodwill. Should Assignee have the Trademark registered in
      its name or name of any other person, Assignor shall have the right to
      have the registration canceled or transferred to Asahi.

            5.10.3 In the event that Assignee learns of any infringement or
      imitation of the Trademark or of any use by any person of any trademark
      similar to the trademark, it promptly shall notify Assignor thereof. If
      requested to do so by Assignor, Assignee shall cooperate with Assignor in
      the protection of Asahi's rights in and to the Trademark. Assignee shall
      have no right to take any action with respect to the Trademark without
      Assignor's prior written approval.

            5.10.4 Upon the termination of this Agreement for any reason
      whatsoever and after Assignee has had a reasonable and sufficient time to
      liquidate its inventory of the Device, Assignee shall, except as Assignor
      may specifically authorize in writing, immediately cease and desist from
      carrying on any and all use of any trademarks, trade names, words or
      symbols of any nature indicating, explicitly or implicitly, that it is an
      authorized distributor or dealer of Assignor's and/or Asahi's products or
      other Assignor and/or Asahi goods and services.

            5.10.5 Any patent, design, copyright and other intellectual property
      rights embodied in the Device shall be the sole property of Assignor or
      the third party designated by Assignor, and Assignee shall not, either
      directly or indirectly, contest nor assist others in contesting the
      validity of such intellectual property rights. Assignor shall be entitled
      to terminate this Agreement forthwith on notice to Assignee if Assignee
      should violate said obligation. Assignee shall not acquire any right in
      the device by execution of this Agreement or performance hereunder or
      otherwise and shall not use any of them after termination of this
      Agreement resulting from expiration of its term or any other cause
      whatsoever.

            5.10.6 Nothing in this Agreement shall be construed as a warranty or
      representation that the Device of the use thereof will be free from
      infringement of any patent or other intellectual property rights of any
      third party. Assignor shall not be under any obligation to defend, or to
      participate in the defense of, Assignee against any claim or suit alleging
      such infringement; provided, however, that Assignor shall, at Assignee's
      costs, cooperate and assist Assignee in the defense of any such claim or
      suit.

      5.11 INDEMNIFICATION AND PRODUCT LIABILITY INSURANCE.

                                      -7-
<PAGE>

            5.11.1 Assignee shall defend and indemnify Assignor against, and
      hold Assignor harmless from, any loss, cost, liability or expense
      (including court costs and reasonable fees of attorneys and other
      professionals) arising or alleged to arise out of the conduct of Assignee
      in connection with Assignee's use, distribution, promotion, technical and
      in-service training, and sale of the Assigned Rights and Technologies;
      provided, however, that (i) Assignee shall have sole control of such
      defense; and (ii) Assignor shall provide notice promptly to Assignee of
      any actual or threatened claim of which Assignor becomes aware.

            5.11.2 Assignor shall defend and indemnify Assignee against, and
      hold Assignee harmless from, any loss, cost, liability or expense
      (including court costs and reasonable fees of attorneys and other
      professionals) arising or alleged to arise out of the conduct of Assignor
      in connection with the distribution of the Assigned rights and
      Technologies; provided, however, that (i) Assignor shall have sole control
      of such defense, and (ii) Assignee shall provide notice promptly to
      Assignor of any actual or threatened claim of which Assignee becomes
      aware.

            5.11.3 Each party shall be responsible for maintaining reasonable
      product liability insurance coverage with respect to the Assigned Rights
      and Technologies in the Territory at all times during the term of this
      Agreement and thereafter until the time when both parties agree upon. Such
      insurance policy shall be written for the benefit of both Assignee and
      Assignor. Assignee shall deliver a certificate of such insurance to
      Assignor promptly upon issuance of said insurance policy.

      5.12 DISTRIBUTION OF OTHER ASSIGNED RIGHTS AND TECHNOLOGIES. Assignor
agrees to enter into distributorship agreements with Assignee or Assignee's
affiliate for the distribution by Assignor to Assignee of any of the Assigned
Right and Technologies, other than the Device (the distribution of which is
provided for herein), for which Assignor holds or owns or will hold or own
distribution and/or marketing rights. Such distributorship agreements shall
provide for the distribution by Assignor of the subject Assigned Rights and
Technologies on terms that are substantially similar to those terms upon which
Assignor receives the subject Assigned rights and Technologies; provided, that,
if commercially viable, such distributorship agreements shall contain terms and
provisions substantially similar to the terms and provisions contained in
Section 5.6 hereof.

      5.13 USE OF THE DEVICE. Assignee hereby agrees to use the Device only for
lawful purposes and uses in accordance with any and all local, state or federal
laws, rules or regulations, including, without limitation, rules and regulations
relating to "good manufacturing practices" promulgated by the United States Food
and Drug Administration.

6. ROYALTY.

      6.1 PAYMENT OF ROYALTY. In consideration of the assignment of the Assigned
Rights and Technologies to the Assignee, Assignee agrees to pay to Assignor a
royalty in an amount equal to five percent (5%) of the Gross Revenues (as
defined herein) (collectively, the "Royalty"). Whenever used herein, "Gross
Revenues" shall mean all revenues of Assignee and an Affiliate of Assignee (as
defined herein) derived from, attributable to, or earned with the use,

                                      -8-
<PAGE>

sale, marketing, development or distribution of the Assigned Rights and
Technologies, including, without limitation, the sale, lease, assignment, or
license of the Assigned Rights and Technologies, less (i) all sales and use
taxes relating to the foregoing; (ii) all paid reserves for returns related to
the foregoing; (iii) all customer rebates related to the foregoing; (iv) all
warranty reserves related to the foregoing; and (v) all charges for freight and
shipping relating to the foregoing.

      When used in this Section 6, "Affiliate of Assignee" shall mean any
individual, sole proprietorship, partnership, joint venture, limited liability
company, trust, unincorporated organization, association, corporation,
institution, entity or party which, directly or indirectly, controls, is
controlled by, or which is under common control with Assignee. Assignee or an
Affiliate of Assignee shall be deemed to be "controlled by" the other if one of
them possesses, directly or indirectly, the power (a) to vote 10% or more of the
securities or interests (on a fully diluted basis) having ordinary voting power
for the election of directors or managers of the other or (b) to direct or cause
the direction of the management policies of the other, whether by contract or
otherwise. Notwithstanding the foregoing, a sales and marketing partner of
Assignee which would otherwise be deemed to be an Affiliate of Assignee shall
not be deemed to be an Affiliate of Assignee, if assignor in its sole
discretion, so consents.

      6.2 DELIVERY OF PAYMENT AND STATEMENTS. Within forty-five (45) days after
the end of each fiscal quarter of Assignee, Assignee shall deliver to Assignor
(i) quarterly financial statements clearly showing the Gross Revenues and (ii)
the payment of the Royalty. Assignee agrees to keep complete and correct books,
accounts and records to facilitate computation of the Royalty.

      6.3 RIGHT TO AUDIT; OVERPAYMENT; UNDERPAYMENT. For the purpose of
verifying the amount of Royalty due, Assignor shall have the right to audit (the
"Audit"), at its expense, the books of Assignee once per calendar year upon the
giving of reasonable notice to Assignee. In the even that the amount of the
aggregate quarterly payments of the Royalty for the time period contemplated by
the Audit are more than the correct amount of the payments of the royalty for
such time period, then the amount overpaid shall be credited to future sales of
the Device. In the event that he amount of the aggregate quarterly payments of
the royalty for the time period contemplated by the Audit are more than five
percent (5%) less than the correct amount of the payments of the Royalty for
such time period, then, in addition to paying to Assignor the amount of the
Royalty previously underpaid, Assignee shall reimburse Assignor for any and all
costs and expenses associated with or related to the Audit.

7. INTELLECTUAL PROPERTY. Assignor accepts, understands and acknowledges that,
for the term of this Agreement, Assignee shall be the owner and holder of, among
other things, any and all intellectual property, including, without limitation,
all present and future rights to market the Assigned Rights and Technologies
within the Market granted by the United States Food and Drug Administration, and
that Assignee shall have the sole right to, among other things, conduct clinical
trials and market the Assigned Rights and Technologies within the Market.

8. FORCE MAJEURE. Except for the prepayment by Assignor pursuant to Section 5.2
of advance payments of Assignee, neither party hereto shall be liable to the
other in any manner for failure or delay in fulfillment of all or part of this
Agreement, or any individual contract, which

                                      -9-
<PAGE>

is directly or indirectly owing to any causes or circumstances beyond that
party's control, including, but not limited to, failure of Asahi to supply the
Device to Assignor, acts of God, governmental orders or restriction, war,
war-like conditions, hostilities, sanctions, mobilization, blockade, embargo,
detention, revolution, riot, looting, strike, lockout, plague or other
epidemics, fire, earthquake, explosion, flood, and shortage of raw materials.

9. TERM. This Agreement shall come into effect as of the date first above
written and shall continue in perpetuity until terminated pursuant to Section
10.

10. TERMINATION.

      10.1 EVENTS OF TERMINATION.

            10.1.1 Assignor may terminate this Agreement and any individual
      contract for the Device hereunder if upon written notice from Assignor to
      Assignee that Assignee is in material default of the terms and provisions
      of the Agreement, Assignee fails to cure such material default within 90
      days after receipt of such notice.

            10.1.2 Assignee acknowledges that the assignment of the rights in
      the Assigned Rights and Technologies to Assignee hereunder shall
      immediately terminate when, and to the extent, Assignor's rights to such
      Assigned rights and Technologies are terminated.

      10.2 EFFECT OF TERMINATION. Termination of this Agreement and/or any
individual contracts for the Device hereunder pursuant to the preceding Section
shall be without prejudice and shall be additional to any right of Assignor
under this Agreement, such individual contracts for the Device, law, statute or
otherwise. Upon termination of this Agreement and/or such individual contracts
for the Device, all payments to be made under this Agreement, including, without
limitation, the payment of the Royalty and/or such individual contracts in
connection with the sale of the Device hereunder shall become immediately due
and payable.

11. MISCELLANEOUS.

      11.1 GOVERNING LAW; FORUM. This Agreement shall be governed by the laws of
the State of Florida. Each party agrees that any suit, action or proceeding
brought by such party in connection with or arising from this Agreement shall be
brought solely in any state or federal court located in Florida, and each party
consents to the jurisdiction and venue of each such court. Each party agrees
that a final judgment in any action or proceeding so brought shall be conclusive
and may be enforced by suit on the judgment or in any other manner provided by
law or equity.

      11.2 EFFECT OF WAIVER. The waiver, express or implied, by either of the
parties hereto of any right hereunder or of any failure to perform or breach
hereof by the other party hereto shall not constitute or be deemed as a waiver
of any other right hereunder or of any other failure to perform or breach hereof
by the other party, whether or a similar or dissimilar nature.

      11.3 ENTIRE AGREEMENT. This Agreement and its Exhibits contain the entire
agreement of the parties with respect to the subject matter herein contained and
supersedes any prior Agreements or understandings between the parties.

                                      -10-
<PAGE>

      11.4 DISPUTE RESOLUTION. Except as provided in Section 3, all disputes,
controversies or differences which may arise between the parties, out of or in
relation to or in connection with this Agreement, or for the breach thereof,
shall be settled by mutual consultation between the parties hereto in good faith
as promptly as possible, but failing an amicable settlement, shall be finally
settled by arbitration to be held in the State of Florida.

      11.5 NOTICES. Unless otherwise provided in this Agreement, all notices to
be given hereunder shall be in writing and sent by facsimile transmission,
overnight courier or registered airmail to the respective addresses of the
parties stated above or to such other addresses as may be indicated in writing
by the parties hereto by notice pursuant to this Section. If either party has
changed its address, a written notice thereof shall be given to the other party
pursuant to this Section.

      11.6 RELATIONSHIP OF THE PARTIES. Nothing in this Agreement shall be
construed or interpreted to provide that Assignee shall or may act as the agent
or legal representative of Assignor for any purpose whatsoever. Assignee is not
granted any right or authority to assume or to create any obligation or
responsibility, expressed or implied, on behalf of, or in the name of, Assignor
or to bind Assignor in any manner whatsoever. Notwithstanding the common
ownership of the equity holders of Assignor, Assignee, OccuLogix, VascuLogix and
NephroLogix, the parties hereto shall remain separate entities.

      11.7 RESPONSIBILITY FOR COSTS INCURRED HEREUNDER. Assignee shall be solely
responsible for all expenses and costs incurred in performing its duties
hereunder, including, without limitation, all of its own operating and sales
promotion expenses.

      11.8 CONDUCT OF ASSIGNEE. the business conducted by Assignee in connection
with the sale, use, marketing, development and distribution of the Assigned
Rights and Technologies shall at all times be conducted and maintained so as not
to detract from, interfere with or adversely reflect upon the goodwill and
reputation of Assignor, the Trademark and/or trade names and Assigned Rights and
Technologies.

                            [SIGNATURE PAGE FOLLOWS]

                                      -11-
<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused this Assignment and
Distributorship Agreement to be executed by their respective duly authorized
representative as of the day and year first above written.

                                           ASSIGNOR:

                                           RheoLogix, L.L.C., a Delaware limited
                                           liability company

                                           By:
                                               ---------------------------------
                                           Its: President & CEO

                                           Apheresis Technologies, Inc.,
                                           a Florida corporation

                                           By: /s/ John Cornish
                                               ---------------------------------
                                           Its: President & CEO

                                           ASSIGNEE:

                                           CytaLogix Corporation, a Delaware
                                           corporation

                                           By:
                                               ---------------------------------
                                           Its: President & CEO

<PAGE>

                                    EXHIBIT A

PRODUCT I

         First filter:     Plasmaflo OP-05W(L)

         Second filter:    Rheofilter AR-2000

Product I means the set of the above first filter and second filter which are
used together.

<PAGE>

                                   EXHIBIT B

PRODUCT II

         Plasmaflo AP-05H(L)

         Hemosorba CH-350

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]